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ABSTRACT

Poor wound healing is a serious medical issue of particular concern in the
elderly and people with diabetes. One major obstacle for these patients to
achieve complete wound healing is incomplete reepithelialization which is
necessary for restoration of barrier function. One molecule that has promising
therapeutic value for promoting reepithelialization is epidermal growth factor
receptor (EGFR). Using a squamous cell carcinoma cell line (SCC 12F) that
expresses moderate levels of EGFR, we investigated the contributions of EGFR
activation to reepithelialization, and specifically its roles in modulation of cell-cell
junctions. Decreased cell-cell adhesion mediated by adherens junctions and
desmosomes is necessary for epithelial outgrowth into the wound area. We find
that elevated EGFR levels are necessary for successful reepithelialization in an
in vitro model. EGFR activation led to junctional and cytoskeletal disruption,
nuclear localization of the junctional protein ß-catenin and upregulation of target
genes involved in wound healing. We also find desmosomes and adherens
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junctions are modulated by different mechanisms. EGF stimulation caused the
desmosomal cadherin desmoglein-2 to internalize and enter a recycling pathway,
while the adherens junction protein E-cadherin underwent a matrix
metalloproteinase-dependent cleavage. We conclude that EGFR can stimulate
multiple mechanisms within a given cell type leading to modulation of cadherin
function, and that the stimulus is an important determinant in junctional protein
fate. Understanding the mechanisms that promote reepithelialization may lead to
strategies to improve wound repair in populations predisposed to poor wound
healing.
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1 Introduction
1.1 Skin Structure
The skin is the largest organ in the human body and has many important
roles including protection of internal organs from the outside environment,
temperature regulation, and fluid retention. The skin is divided into the dermis
and the epidermis (Figure 1.1.1). The dermis consists of connective tissue, and
is the location of hair follicles, sweat glands and blood vessels (Bolognia et al.,
2003). Located within the dermis, there are several appendages that contain
niches of stem cells, including the bulge region of the hair follicle, and sebaceous
glands (Figure 1.1.1). Connecting the epidermis to the dermis is the basement
membrane, which is composed of extracellular matrix proteins such as collagen
and laminin. The epidermis has 5 layers and in each layer the epithelial cells, or
keratinocytes, have different phenotypes and characteristics based on
differentiation status (Figure 1.1.1). The first layer of the epidermis in contact
with the basement membrane is the stratum basale, which consists of columnar,
proliferating epithelial cells (Bolognia et al., 2003). These cells proliferate for a
few cycles, then migrate and differentiate to form the suprabasal layers where
they lose their ability to proliferate (Gurtner et al., 2008).
Maintenance of the epidermis depends on intrafollicular stem cells, which
are interspersed in the basal layer between hair follicles. Although stem cells also
exist within the hair follicle and the bulge region of the hair follicle (Figure 1.1.1),
they are responsible for maintenance of the hair follicle and do not contribute to
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the intrafollicular epidermis (Watt et al., 2006). However, the existence of
intrafollicular stem cells is now under debate. Until recently, intrafollicular stem
cells were believed to be the progenitor cells of transit amplifying cells, which are
located at the basal layer and undergo several rounds of proliferation before
committing to terminal differentiation (Watt et al., 2006). Recent studies support
a new model; the committed progenitor cell that proliferates like a stem cell but is
committed to terminal differentiation similar to a transit amplifying cell (Clayton et
al., 2007; Jones and Simons, 2008).
Whatever their origin, once cells are committed to differentiation, they
migrate to the subrabasal layers, beginning with the stratum spinosum, which is
directly above the stratum basale (Fig. 1.1.1). The stratum spinosum is
composed of several layers of cuboidal epithelial cells that produce large
amounts of cytokeratin. The next layer above the stratum spinosum is the
stratum granulosum, which is named due to the granules visible by light
microscopy and is the uppermost layer containing living cells. The next layer, the
stratum lucidum, is only present in thick skin such as the soles of feet and the
palms of hands, and is made up of a clear layer of cells that lack internal
organelles. The last layer is the stratum corneum, which consists entirely of
denucleated keratinocytes. These cells are continuously sloughed off and are
replaced as cells differentiate from the proliferating stratum basale up through the
strata to the stratum corneum (Bolognia et al., 2003).
Other cells present in the epidermis include melanocytes and Langerhans
cells. Melanocytes produce melanin, which lends the skin its pigmentation and
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provides partial protection from ultraviolet radiation (Bolognia et al., 2003).
Langerhans’ cells are the immune cells of the epidermis that upon encountering
a foreign substance, break it down into peptides that subsequently enter the
lymph system and act as antigens for the immune system (Bolognia et al.,
2003). Taken together, the epidermis is a complex tissue with several different
cell types that work together to respond to environmental insult in order to
maintain skin integrity and function.
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Figure 1.1.1
Layers of the Skins
Schematic representation of the several layers of the epidermis. Starting from the bottom of the
figure is the dermis, which contains the hair follicle and sebaceous glands. Directly above the
dermis is the basement membrane. Directly above the basement membrane is the proliferating
basal layer termed the stratum basale. The stratum spinosum represents the layer in which the
keratinocytes start to differentiate and produce cytokeratin. The stratum granulosum is so named
for the granular structures present, and is the last layer of fully differentiated, living cells. The
stratum lucidium is present only in thick skin, and is named for its clear appearance under the
microscope. Finally, the uppermost layer, the stratum corneum, is made up of dead, denucleated
keratinocytes, and whose contents are mostly keratin.
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1.2 Wound Repair
When a wound is introduced into the skin, it compromises the intact barrier
function and opens up the body to threats such as water loss (dehydration) and
increased susceptibility to infection (Coulombe, 2003). The progression of
wound healing is an intricate interplay of different systems working in concert and
has several stages that takes weeks to accomplish (Singer and Clark, 1999).
The basic steps include clotting, inflammation, reepithelialization, remodeling of
the extracellular matrix, and contraction of the wound (Figure 1.2.1). Within
minutes after the initial injury, platelets invade into the wound area and form a
clot by releasing thrombin, which cleaves fibrinogen and forms a crosslinked
network of fibrin fibers (Dvorak, 1988). It is this resulting clot (Figure 1.2.1, step
1.) that covers the wound area and protects it from further external damage
(Martin, 1997). Inflammation and the deposition of granulation tissue follow the
appearance of inflammatory cells, fibroblasts and capillaries into the wounded
area. Within minutes after wounding, neutrophils enter the wound area and the
corresponding pro-inflammatory cytokines are released (Singer and Clark, 1999).
It is these neutrophils and platelets that aggregate in the clot and release factors
that stimulate cell motility and proliferation in the surrounding keratinocytes and
fibroblasts (Eming et al., 2007). The next set of inflammatory cells that invade
are macrophages, which also release cytokines and growth factors and
phagocytose any outside contamination that may have been introduced into the
wound area. The macrophages also phagocytose excess cell and matrix debris
that accumulates as part of the wound healing process (Singer and Clark, 1999),

5

including the neutrophils that are no longer necessary (Eming et al., 2007). The
signals and factors produced by macrophages induce both keratinocytes and
fibroblasts to produce granulation tissue (Figure 1.2.1, step 2). Keratinocytes
produce granulation tissue components collagen IV and laminin-5, whereas
fibroblasts produce nidogen and small amounts of collagen IV (Werner et al.,
2007). It is this granulation tissue, or matrix, that the epithelial cells will migrate
on during reepithelialization.
Reepithelialization, or the formation of a functional epithelial barrier, occurs
a few days after the initial injury and involves the proliferation and migration of
epithelial cells (keratinocytes) into the wound area (Figure 1.2.1, step 3). During
this time period (24 hours to several days) the granulation tissue is remodeled to
resemble a traditional extracellular matrix (ECM) (Singer and Clark, 1999).
Capillaries provide blood supply to the granulation site, and new capillaries
migrate as branches from intact capillaries in the area around the wound (Baum
and Arpey, 2005). Fibroblasts also serve as a contractile mechanism and pull
the two opposing sides of the wounded tissue closer together (Figure 1.2.1, step
4) (Singer and Clark, 1999). Platelets release platelet derived growth factor
(PDGF) and transforming growth factor beta (TGF-ß), which cause fibroblasts to
differentiate into myofibroblasts that have contractile properties used during
wound healing (Werner et al., 2007). Finally, it takes weeks to months for the
dermis and epidermis to fully mature (Figure 1.2.2), which is accompanied by
regeneration of hair and sweat glands (Martin, 1997), a decrease of type I
collagen and an increase of type III collagen (Baum and Arpey, 2005).
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Figure 1.2.1
Reepithelialization of a healing wound
Stages of wound repair begins with (1) production of a fibrin clot to cover the wounded area and
protect it from the outside environment. The second stage is (2) invasion of inflammatory cells
into the wound area and the formation of granulation tissue. It is on this granulation tissue that
the epithelial cells can migrate across in the third stage, reepithelialization (3). Finally, the
fibroblasts of the dermis can also participate by contracting the wound area (4), and remodeling
of the wound area can continue, for up to weeks after the initial wound. For description of growth
factors and cytokines and their roles in promoting wound healing, see figure 1.4.1 and sections
1.3 and 1.4 in the text.
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Figure 1.2.2
Overview of Wound Healing
Wound healing goes through several different stages, some of them occurring concurrently in
order to restore the damaged tissue to a functional epidermis. Within minutes, clotting factors
work to provide a temporary barrier. Next, inflammatory cells infiltrate the area and deposit
granulation tissue, on which keratinocytes can proliferate and migrate upon in order to produce a
“functional restoration” of the epithelial barrier. Weeks to months later, the dermis undergoes
remodeling of the granulation tissue in a process that ultimately results in scar tissue formation.
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1.3 Modulators of Wound Repair
Throughout the stages of wound healing there are many modulators
present that activate various cell types and orchestrate wound repair. These
factors include steroid hormones, cytokines and growth factors. Each class of
modulators has an impact on several phases of wound healing.

1.3.1

Steroid Hormones

Glucocorticosteroids and the sex hormones are two types of steroid
hormones that modulate wound healing. Glucocorticosteroids have been studied
for many years, and there are several findings that have come of their use with
respect to wound healing. Sex hormones estrogen and testosterone, as well as
their precursor DHEA, have not been studied as extensively, but significant
findings of these hormones and their effects on wound healing have been
revealed in the last 10 years.
Glucocorticosteriods are a class of therapeutics first used in the 1950’s for
the treatment of several different skin disorders, until severe adverse effects
were reported as early as 1955 (Hengge et al., 2006). Adverse cutaneous
effects included a desensitization of the skin (tachytphylaxis), increased fragility,
easy bruising, and poor wound healing (Hengge et al., 2006). Excess
glucocorticosteroids lead to dramatic effects on several areas of wound healing,
including less granulation tissue, decreased collagen synthesis, decreased
inflammatory response, and a decrease in proliferation of fibroblast and
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keratinocytes (Reed and Clark, 1985). The decrease in collagen synthesis led to
reduced tensile strength in the wounded skin (Beer et al., 2000a). Specifically, in
glucocorticoid treated skin, cytokines interleukin-1 alpha and beta (IL-1α, IL-1ß),
and tumor necrosis factor alpha (TNF-α) mRNA levels were decreased at the
wound margin (Hubner et al., 1996a), as well as several growth factors including
keratinocyte growth factor (KGF) (Brauchle et al., 1995), PDGF, TGF-ß1, and
TGF-ß2 (Beer et al., 2000a). Glucocorticosteroid treatment caused chronic
wounds in animal studies, which presented ulcers similar to those seen in
diabetic patients (Bitar, 1998). Although the exact mechanism of glucocorticoid
mediated disruption of wound repair is unknown, studies found that treatment
with glucocorticoids compromises epidermal permeability (Kao et al., 2003) and
suppressed several genes key in wound healing, including those in the immune
response and matrix remodeling as seen by microarray analysis (Stojadinovic et
al., 2007).
Sex hormones represent another type of steroid hormones that can have an
effect on wound healing. Estrogen is a positive regulator of wound healing that
decreases the immune response (Gilliver et al., 2007). Specifically, estrogen
decreased an inflammatory response by downregulating the macrophage
migration inhibitory factor (MIF) (Ashcroft et al., 2003). Decreasing the immune
response is important in wound healing because an increased or prolonged
inflammatory period corresponds with poor wound closure (Wang et al., 2006).
In addition, estrogen increased keratinocyte migration and induced endothelial
cells to form capillary-like structures in cell culture. (Gilliver et al., 2007). A
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decrease in the estrogen and androgen hormone precursor
dehydroepiandrosterone, (DHEA), correlated with impaired healing in human
studies, and addition of DHEA reversed the delay of wound healing seen in aged
mice (Mills et al., 2005), via conversion to estrogen and activation of the estrogen
receptor. In contrast to estrogen, testosterone had a negative effect on wound
healing. Removal of testosterone by the castration of male mice resulted in
faster healing compared to that of their control littermates (Ashcroft and Mills,
2002). The metabolically active form of testosterone, 5-α-dihydrotestosterone
(DHT) is believed to be responsible for the delays in wound healing, as inhibition
of this conversion increased wound healing to the same rate as castrated
littermates (Gilliver et al., 2006). In both mice and rats, castration decreased the
immune response and collagen deposition, two events that can lead to
detrimental effects in wound healing if overstimulated (Gilliver et al., 2007).
Steroid hormones can be both positive and negative regulators of wound
healing. Estrogen and its precursor DHEA enhance wound healing which could
prove to be a beneficial side effect for postmenopausal women on hormone
replacement therapy. Testosterone and glucocorticoids have negative effects on
wound healing and caution should be used in prescribing glucocorticoids to
populations disposed to poor wound healing. Gender differences in wound repair
occur among elderly populations (Ashcroft et al., 1999), and the prevention of the
development of chronic wounds occurs in postmenopausal women on hormone
replacement therapy (Ashcroft et al., 2003).
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1.3.2

Cytokines

Cytokines are small, secreted proteins that can modulate cells of the
immune system and represent another group of molecules that regulate wound
healing. A brief summary of abbreviations is available for reference on page xi.
Proinflammatory cytokines involved in wound repair and specifically
reepithelializaton include IL-1, interleukin 6 (IL-6), granulocyte-macrophage
colony-stimulating factor (GM-CSF), and TNF-α, all of which are upregulated
during the inflammatory phase of wound healing (Werner and Grose, 2003).
Chemokines are a subset of cytokines and a number of them are regulated
during wound healing, which will be discussed independently in section 1.3.3.
The inflammatory response is a major step in wound healing and the activation of
this pathway is mediated mainly by proinflammatory cytokines, although reports
indicate the importance of anti-inflammatory cytokines as well. Most of these
cytokines (IL-1, IL-6, GM-CSF, IL-10) are beneficial to wound healing, but some,
such as TNF-α, impair wound healing. The focus in this section will be on those
that have a positive or negative effect on reepithelialization and are produced by
keratinocytes.
IL-1 is a proinflammatory cytokine that exists in two isoforms, IL-1α and IL1β. It is produced by keratinocytes, and is normally stored in the cytoplasm at
low levels until signaling occurs such as in response to wounding. The
keratinocytes then release IL-1 as evidenced by mRNA and protein expression in
vitro (Hubner et al., 1996a; Sabourin et al., 2000) and in vivo wounding studies
(Sabourin et al., 2000) into the surrounding environment activated not only
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themselves in an autocrine manner, but also activated dermal fibroblasts and
endothelial cells (Wood et al., 1996). IL-1 is considered the initiator of the
keratinocyte activation cycle that keratinocytes undergo under wounded
conditions. Entering this cycle, keratinocytes became hyperproliferative,
migratory, and change keratin isoform expression in a process called a keratin
switch (Freedberg et al., 2001).
IL-6 is a proinflammatory cytokine produced by several cell types, including
keratinocytes, fibroblasts and macrophages (Lin et al., 2003). Transcripts of this
cytokine were increased as early as 3 hours after wounding and persisted for
over 72 hours in an in vivo porcine wounding model (Sabourin et al., 2000).
Studies found that IL-6 did not directly induce keratinocyte migration, as was
previously believed, but instead acted indirectly by activating STAT-3
phosphorylation in fibroblasts that then caused release of an as yet unknown
factor that stimulated keratinocyte migration (Gallucci et al., 2004). In gene
deletion studies, lack of this cytokine delayed reepithelialization, which was
rescued by adding back recombinant IL-6 one hour prior to wounding (Werner et
al., 2007). Recent studies showed that IL-6 acted as an inducer of fibroblast
migration into granulation tissue, as IL-6 deficient mice show decreased
fibroblast motility (Luckett and Gallucci, 2007).
GM-CSF is a pleiotropic cytokine secreted by keratinocytes in response to
wounding (Mann et al., 2001). Clinically, GM-CSF was applied intradermally to
leprosy patients with skin lesions that led to increased keratinocyte production
and enhanced overall wound healing (Holman and Kalaaji, 2006).
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Overexpression of a GM-CSF antagonist in the epidermis resulted in poor wound
healing, as evidenced by delayed reepithelialization due to reduced keratinocyte
proliferation, as well as reduced neovascularization and collagen deposition
(Mann et al., 2006). Similiarily, genetic deletion of GM-CSF also resulted in poor
wound healing as evidenced by delayed reepithelializaion and collagen
deposition (Fang et al., 2007). These studies indicate the importance of GMCSF regulation during reepithelialization.
TNF-α is a proinflammatory cytokine whose mRNA is upregulated in wound
margin epithelium (Hubner et al., 1996a), but is mainly produced by
macrophages in the granulation tissue (Hubner et al., 1996a) and by neutrophils
in the first few hours after wounding (Gillitzer and Goebeler, 2001). However,
unlike the previously mentioned cytokines, reduced signaling of this cytokine
resulted in enhanced wound repair. Gene deletion of the receptor of this
cytokine, TNF receptor p55, resulted in decreased leukocyte infiltration into the
wound, yet accelerated wound repair (Eming et al., 2007). Consistent with these
results, Goren et al. used a mouse model ob/ob to induce diabetic wound ulcers,
and then treated these ulcers with an anti-TNF-α antibody to functionally block
TNF-α signaling (Goren et al., 2007). They found increased wound healing and a
decrease in the numbers of macrophages in the wound site.
IL-10 is an anti-inflammatory chemokine that in addition to being produced
by infiltrating mononuclear cells, is also produced by keratinocytes in the wound
epidermis (Sato et al., 1999). IL-10 is a chemokine that works by suppressing
the immune response by inhibiting synthesis of several proinfammatory cytokines

14

in both macrophages and neutrophils (Werner and Grose, 2003). IL-10 mRNA
levels were upregulated by 1 hour post wounding in a murine incision model and
protein levels were increased in a biphasic response, with the first surge
occurring 3 hours post incision and the second occurring 72 hours post wounding
(Sato et al., 1999). Use of neutralizing antibodies against IL-10 at the wound
margin revealed that IL-10 suppressed the response of several chemokines,
including monocyte chemoattractive protein (MCP), macrophage inflammatory
protein 1 alpha (MIP1-α), and IL-6. (Sato et al., 1999). This suppression might
be required in the later stages of wound healing and for the formation of scar
tissue. Inhibition of of IL-6 and IL-8 by IL-10 occured in fetal wound repair, which
is scarless (Eming et al., 2007). When IL-10 knockout skin was grafted onto
embryos, a large inflammatory response and adult like scarring occurred (Liechty
et al., 1998). These studies illustrate the importance of IL-10 in regulating
proinflammatory chemokines at the wound site.
The inflammatory response is a step in wound healing that is mediated by
several different molecules including the proinflammatory cytokines.
Keratinocytes themselves produce cytokines associated with inflammation, which
in turn affect keratinocyte migration and modulate the wound environment.
Understanding both the positive and negative roles that cytokines play in wound
healing will ultimately provide information that is beneficial clinically. Also,
recognizing the time frame of wound healing and in particular the release of
cytokines in healing wounds will ultimately help in accelerating wound healing
and eliminating scar tissue.
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1.3.3

Chemokines

Chemokines represent a subset of cytokines expressed during wound
repair. Chemokines are cytokines that stimulate chemotaxis of leukocytes during
the inflammatory response. Chemokines can be divided into 3 different classes
based on their folding and separation of two disulfide bonds between 4 cysteine
residues. The CXXC class has two amino acids in between the two disulfide
bonds, the CXC class, has one amino acid separating the bonds and the CC
class has no amino acid between the two disulfide bonds. Due to the large
number of chemokines involved in wound healing, only those that directly bind to
or are produced by keratinocytes will be reviewed and these will be further
separated by either the positive or negative effect they have on
reepithelialization.
Chemokines that are produced in another cell type but affect keratinocytes
and reepithelialization include growth related oncogene alpha (GRO-α) and
interleukin 8 (IL-8). GRO- α and IL-8 are both members of the CXC class of
chemokines. GRO-α, also known as CXCL1, or macrophage inflammatory
protein 2 (MIP-2), was elevated after wounding in vivo and in vitro and was a
strong mitogen for keratinocytes (Gillitzer and Goebeler, 2001). GRO-α mRNA
expression was upregulated in both human excisional (Engelhardt et al., 1998)
and burn wounds, at time points that correlated with keratinocyte migration
(Werner and Grose, 2003). However, in human burn patients, the exogeneous
application of GRO-α impaired wound contraction, so further study is needed to
clarify the positive and negative effects of GRO-α in wound healing. The
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receptor for both GRO-α and IL-8 is named CXCR2. This receptor is expressed
on keratinocytes, and in gene deletion studies, mice without this receptor showed
delayed reepithelialization and neovascularization in response to full thickness
excisional wounds (Devalaraja et al., 2000). It appears that both GRO-α and
CXCR2 have roles in the inflammatory response, angiogenesis and
reepithelialization during the process of wound healing.
IL-8 has no known murine homolog as of yet, but it has been studied in vitro
and in vivo with human keratinocytes and patient samples, respectively. In vitro
studies showed that IL-8 stimulated both keratinocyte migration and proliferation
(Raja et al., 2007). In human wound samples, IL-8 mRNA levels were increased
by day one post wounding as visualized by in situ hybridization (Gillitzer and
Goebeler, 2001). However, high levels of IL-8 were associated with non healing
burn wounds, and the same levels inhibited keratinocyte proliferation in culture,
(Raja et al., 2007). It appears that strict regulation of this chemokine is
necessary during reepithelialization.
There is only one chemokine known to be produced by keratinocytes, the
CC chemokine monocyte chemattractant protein (MCP-1), also known as CCL2.
Keratinocytes are the major source of MCP-1 in wounded epidermis (Engelhardt
et al., 1998). Upregulation of MCP-1 occured in a timeframe that corresponded
with macrophage infiltration (Gillitzer and Goebeler, 2001), suggesting a
keratinocyte role in macrophage recruitment during wound healing. Treatment of
mouse wounds with this chemokine increased the number of macrophages at the
wound site, and this number can be reduced by neutralizing antibodies against
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MCP-1 (Werner and Grose, 2003). However, transgenic mice lacking MCP-1
had normal numbers of macrophages in the wound area, suggesting that other
chemokines might be released to compensate for the lack of MCP-1. Supporting
this view, investigators found upregulation of several chemokines and chemokine
receptors in wounds when comparing MCP-1 knockouts to wild type mice
(Ferreira et al., 2005). Reepithelialization in these mice was delayed, suggesting
that MCP-1 plays a role in both macrophage recruitment and reepithelialization.
Overall, there are a number of modulators (steroids, cytokines,
chemokines) that play a variety of roles in wound healing, including macrophage
recruitment, angiogenesis, reepithelialization, and scar formation. In each
category, both positive and negative regulators exist. A clearer understanding of
how these and other factors work together in wound healing could provide helpful
strategies in both normal wound healing and in chronic wounds.

1.4 Peptide Growth Factors
Peptide growth factors are another large family of molecules that are
strongly upregulated in response to wounding. Peptide growth factors involved in
wound healing can be divided into tyrosine kinase receptor ligands, and nontyrosine kinase receptor ligands. This section is limited to those growth factors
that are produced by keratinocytes or those that are produced by other cells but
directly impact reepithelialization. This includes both non receptor tyrosine
kinase ligands, and receptor tyrosine kinase ligands.
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1.4.1

TGF-ß Family

The transforming growth factor-beta (TGF-ß) superfamily of ligands
represents the best studied and largest family of non tyrosine kinase receptor
ligands. TGF-ß family members include TGF-ß, activins, bone morphogenetic
proteins (BMPs), Mullerian inhibiting substance, nodals, and inhibins. TGF-ß,
activins and BMPs are the classes that have been studied in wound healing, and
will be the focus in the following paragraphs.
TGF-ß exists as three isoforms (TGF-ß1, -ß2. -ß3) that are ligands for the
TGF-ß receptor complex. The receptor complex consists of two serine/threonine
receptors, designated type I and type II, which form a heterodimer, that once
bound to ligand, stimulate signaling cascades such as the Smad pathway
(Werner and Grose, 2003). TGF-ß3 serves to downregulate the other two
isoforms, which are implicated in the formation of scars (Martin, 1997). In
addition, TGF-ßs also bind type III receptor, which is non-signaling and functions
to present TGF-ß to the type II receptor.
TGF-ß is released from platelets in the wound, and stimulates fibroblast
proliferation and differentiation into myofibroblasts (Werner and Grose, 2003).
During wounding, TGF-ß causes keratinocytes to switch their integrin profile to
allow for migration to occur (Freedberg et al., 2001). Keratinocytes upregulated
the TGF-ß receptor complex in response to wounding (Zambruno et al., 1995).
The most profound effect of the TGF-ß family on wound healing is their impact on
the formation of scar tissue. Wounds in embryonic tissue heal without scarring,
and TGF-ß is absent in these wounds (Redd et al., 2004). Addition of
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neutralizing antibodies against TGF-ß1 and -ß2 or the addition of exogenous
TGF-ß3 at the time of wounding reduced the amount of scarring in a rat
wounding model (Shah et al., 1994, 1995). Experiments comparing TGF-ß (1-3)
in normal dermal wounds versus oral mucosal wounds, which presented with
quicker healing and less scar tissue, revealed a difference in the expression
profile of these three isoforms (Schrementi et al., 2008). Oral mucosal wounds
had higher levels of TGF-ß3, which functionally blocks the other two isoforms.
No differences were seen with TGF-ß2, but TGF-ß1 levels were higher in dermal
wounds than in the oral mucosal wounds, again consistent with the idea that
increased levels of TGF-ß1 correlates with increased scarring.
Studies to separate the effects of the inflammatory response and TGF-ß are
difficult due to the fact that creating TGF-ß null mice causes the mice to die
anywhere from 10 days to 3 weeks of age (depending on genetic background)
due to a severe wasting syndrome (Grose and Werner, 2004) (Brown et al.,
1995). These mice have an extreme inflammatory response that results in tissue
necrosis and multiorgan failure shortly after birth. Researchers used the
immunosuppressive drug rapamycin to prolong the life of these transgenic mice
to 60 days, and another group used an immunodeficient, Scid -/- mouse in order
to tackle this problem (Grose and Werner, 2004). Wounding in these two
different models led to different results. The rapamycin treated mice had
enhanced healing with scabless wounds and increased reepithelialization. The
TGFß1 -/- Scid -/- mice, however, had delayed reepithelialization as compared to
the TGF ß1 +/+ Scid -/- controls. One possibility for these observed differences
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is a positive affect rapamycin could be playing during wound healing on nonimmune cells.
Overexpression of TGF-ß1 in mice gave mixed results depending on the
method employed. Researchers overexpressed a constitutively active form of
TGF-ß1, but found that even though the circulating plasma levels of TGF-ß1
were increased in these mice, there was no increase of TGF-ß1 at the site of
wounding (Grose and Werner, 2004). Shah and coworkers overexpressed a
latent form of TGF-ß1 under a keratin promoter so that it would be expressed in
the skin. Wounding of these mice resulted in higher levels of TGF-ß1 at the
wound site, decreased keratinocyte proliferation and delayed reepithelialization
as compared to controls (Shah et al., 1999). Recently, overexpressesion of
TGF-ß1 under the keratin 5 promoter showed delayed wound healing and
increased inflammation during all stages of wound healing (Wang et al., 2006).
Clearly, TGF-ß isoforms have several overlapping and opposing roles
during the many processes of wound healing. TGF-ß1 and -ß2 are important in
activating the immune response, but extended activity seems to lead to scar
formation. TGF-ß3 serves as a checkpoint for this system, by antagonizing the
effects of isoforms ß1 and ß2, yet in adult tissue, scarring still occurs. Further
research is needed to clarify the roles of TGF-ß in wound healing and maximize
the positive effects (keratinocyte migration) while minimizing the negative effects
(scarring).
Activins are members of the TGF-ß family, and exist as dimeric proteins,
with the monomers linked together by disulfide bonds. There are 3 isoforms of

21

activin, named activin A with the monomers ßA ßA , activin B, that contains the
monomers ßB and ßB, and activin AB, containing the monomers ßAßB (Wankell
et al., 2003). The receptors for activins can be separated into type I (ActRI) and
type II (ActRII), and there are A and B isoforms of each type. Upon wounding,
mRNA of both activin B subunits ßA and to a lesser extent ßB are upregulated in
keratinocytes at the migrating wound edge without an increase in their
corresponding receptor (Hubner et al., 1996b). Overexpression of the ßA subunit
resulted in increased keratinocyte proliferation and enhanced wound healing,
particularly in the process of granulation tissue formation (Beer et al., 2000b).
These same researchers identified the transcription factor MAD1, a known
antagonist of c-Myc, as a novel downstream target of both activin and TGF-ß1 in
both keratinocytes and leukocytes post wounding (Werner et al., 2001). Activin
knockout mice died shortly after birth, but investigators have found the protein
follistatin to be a natural antagonist to activin. Overexpressing the activin
antagonist in the skin led to a large reduction in the amount of granulation tissue.
Furthermore, the hyperproliferative wound epithelium was thinner, although
reepithelialization was not delayed (Wankell et al., 2001). Gene deletion of
follistatin in keratinocytes resulted in increased keratinocyte proliferation during
the early stages of wound healing, but the overall timeframe of reepithelialization
was not affected (Antsiferova et al., 2008). In summary, activins are relatively
newly discovered regulators of wound healing, and results so far suggest their
contributions to wound healing lie in the formation of granulation tissue, and not
in reepithelialization.
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Bone morphogenetic proteins (BMPs) are the third class in the TGFß
superfamily known to affect wound healing. Although several BMPs (-2, -4, -6, 7) are expressed in the skin (Wankell et al., 2001), only BMP-2 and BMP-6 have
shown differences in wound healing experiments (Werner and Grose, 2003).
Fetal wound repair is scarless when it occurs in the first two trimesters, and since
TGF-ß is known to induce scarring when added exogenously to a fetal wound
(Piscatelli et al., 1994), investigators wanted to see if the TGF-ß family member
BMP-2 had any deleterious effects on fetal wound repair. Normal uninjured fetal
epidermis expressed very low levels of BMP-2, and addition of exogenous BMP2 to injured fetal tissue resulted in scar formation (Stelnicki et al., 1998). One
explanation for these differences between adult and fetal wound healing is the
wound area. Fetal wounds tend to have a small surface area, and closure
occurs predominantly by contraction of the actin cable surrounding the wound
edge in a purse-string mechanism (Martin, 1997). Adult wounds are larger and
require epidermal cell migration into the wound area. This process requires
signaling events stimulated by numerous growth factors. One consequence of
this increased signaling is scarring, which is hypothesized to occur due to an
immune response stimulated by these wound-associated factors. In contrast,
fetal tissue does not scar due to the lack of a mature immune system (Gurtner et
al., 2008).
BMP-6 is a ligand that is upregulated in keratinocytes proximal to the
wound edge 3 days after wounding (Kaiser et al., 1998), and to investigate its
role, Kaiser et al. overexpressed BMP-6 in the epidermis, then performed wound
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healing experiments. BMP-6 overexpressing mice showed delayed wound
healing, in particular a delay in reepithelialization (Kaiser et al., 1998). Further
research is needed to clarify the role of this ligand in wound healing, since it is
upregulated in proximal keratinocytes during wound healing but overexpression
delays wound healing.
The TGF-ß superfamily has several members that participate in wound
healing, including TGF- ßs, activins and BMPs. Persistent themes across these
subfamilies include the modulation of the immune response, contribution to the
scarring response and excess of these ligands inhibit reepithelialization. It
appears that successful wound healing requires a fine tuning of these ligands,
and future research into these ligands appears to be logical route to accomplish
scarless adult wound healing.

1.4.2

Receptor Tyrosine Kinases

A number of peptide growth factors elicit their effects through receptor
tyrosine kinases (RTKs). There are several classes of RTK’s, and only those
involved in wound healing will be reviewed (See figure 1.4.1). Growth factors are
separated into those produced by keratinocytes, and those produced in other cell
types but directly affecting keratinocytes and reepithelialization. The epidermal
growth factor (EGF) and its receptor is a growth factor family that is well studied
in wound healing and will be discussed in section 1.5.
There are several growth factors produced by keratinocytes that work in a
paracrine fashion to affect neighboring cell types to enhance wound healing.
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Platelet derived growth factor (PDGF), hepatocyte growth factor (HGF), vascular
endothelial growth factor (VEGF), and nerve growth factor (NGF), were first
discovered in other cell types, but are also produced by keratinocytes in
response to wounding (Matsuda et al., 1998; Cross and Mustoe, 2003; Werner et
al., 2007). These growth factors are secreted into the wound area and can
stimulate fibroblast proliferation and migration, the production of granulation
tissue, and angiogenesis, and keratinocyte proliferation.
Platelet derived growth factor (PDGF), like TGF-ß, is released by platelets
in response to wounding minutes after injury. There are five isoforms of the
PDGF family named PDGF-AA, -AB, -BB, -CC, and -DD, and three PDGF
receptors. PDGF stimulated fibroblasts to differentiate into myofibroblasts and
facilitated the dermal contraction of the wound (Werner et al., 2007). It was one
of the first growth factors discovered to be important in wound healing, and it was
found in wound fluid from pediatric burn patients (McCarthy et al., 1996). Both
mRNA levels and protein levels of PDGF ligands and their corresponding
receptors were upregulated in porcine (Antoniades et al., 1991), and human
(Ansel et al., 1993; Reuterdahl et al., 1993) keratinocytes during wound healing.
In a diabetic mouse model mice exhibited chronic, nonhealing wounds. Upon
examination, these mice had lower levels of both PDGF-A and its receptor than
normal mice (Beer et al., 1997). Upon wounding, expression of PDGF-A
decreased even further, suggesting that a lack of this growth factor could
contribute to the failure of these wounds to heal. PDGF-B mRNA and protein is
upregulated in human keratinocytes after trichloroacetic acid treatment (Yonei et
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al., 2007). PDGF-B is the only growth factor approved as a drug for chronic
wound treatment, and a clinical trial using an adenovirus-PDGF-B vector has
shown success in patients with diabetic ulcers (Barrientos et al., 2008).
PDGF-B and B receptor null mice are both embryonically lethal, so in order
to study the effects of this deletion in adult mice, investigators irradiated the
hematopoietic system of adult mice and replaced these cells with those from
PDGF-B null mice (Buetow et al., 2001). No changes in granulation tissue
formation occurred in these mice, and vascularization of the wounded area was
increased in this system. The lack of PDGF-B in the wound area delivered by
endothelial cells could be compensated by production of PDGF-B by
macrophages and keratinocytes. However, overexpression of PDGF was
evident in hypertrophic scars and keloid tissue (Werner and Grose, 2003),and
PDGF-A worked against the positive effects of EGF when both were applied
exogenously during wound healing (Gope, 2002). indicating the need for
regulation of this growth factor for normal wound repair.
Hepatocyte growth factor (HGF), also known as scatter factor (SF) or
plasminogen-related growth factor (PRGF), has only one other known family
member, macrophage stimulating protein (MSP), also known as hepatocyte
growth factor like protein (HGFL), SF2, or PRGF2. HGF was first discovered in
hepatocytes, although it was later found to stimulate keratinocyte migration and
proliferation upon binding to its tyrosine kinase receptor cMET (Conway et al.,
2007). It is due to this discovery that a role in wound healing was postulated. In
a rat wound model, upregulation of HGF and its receptor cMET was observed in
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both keratinocytes and in the granulation tissue of healing wounds (Werner and
Grose, 2003). HGF appears to play an key role in granulation tissue formation,
as overexpression of HGF in transgenic mice revealed enhanced granulation
tissue formation after wounding, but did not enhance reepithelialization (Werner
and Grose, 2003). In patient samples, expression of HGF, cMET, and their
regulators are detected in both acute and chronic wounds, however, differences
in the expression levels and areas of expression differed between the two wound
types (Conway et al., 2007). It can be concluded that HGF is a vital growth factor
in wound healing, but its effects are mostly on granulation tissue formation rather
than reepithelialization.
The vascular endothelial growth factor (VEGF) family of ligands is
comprised of 6 known members to date, VEGF-A, VEGF-B, VEGF-C, VEGF-D,
VEGF-E, and placenta growth factor (PLGF). They exert their effects on three
different receptors, VEGFR-1, VEGFR-2, and VEGFR-3. VEGF-A and PLGF are
both produced by keratinocytes (Werner and Grose, 2003), and the VEGFR-1
receptor was upregulated in both murine and human keratinocytes following
wounding (Wilgus et al., 2005). VEGF-A neutralizing Ab caused delayed
angiogenesis in an abdominal hernia wounding model as observed by decreased
wound vessel count and vascular surface area (Howdieshell et al., 2001).
Keratinocytes produced PLGF mRNA in response to wounding from day 3 to day
5 post wounding (Failla et al., 2000). PLGF knockout mice displayed poor wound
healing due to a delay in angiogenesis (Carmeliet et al., 2001). Although most
studies show that VEGF family members primarily effect angiognesis, studies
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using a neutralizing antibody against VEGFR-1 showed delayed
reepithelialization, possibly by inhibiting keratinocyte proliferation, as the number
of proliferating keratinocytes were reduced in the presence of the anti-VEGFR-1
antibody (Wilgus et al., 2005).
Nerve growth factor (NGF) was first thought to participate in wound healing
when it was found in high levels in the saliva, and that the licking of wounds
enhanced wound contraction (Werner and Grose, 2003). NGF levels in wounded
mice occured in both the serum and at the wound site, with maximal serum levels
occurring 6 hours post wounding and maximal skin levels occurring 24 hours
post wounding (Matsuda et al., 1998). Serum levels were deterimined to
originate from salivary gland production, while skin levels of NGF were
determined to come from both fibroblasts and keratinocytes (Matsuda et al.,
1998). Basal, proliferating keratinocytes were positive for mRNA expression 3
days post wounding, while NGF protein was detected in the superficial,
differentiated keratinocytes at this same time point. These investigators then
treated non-healing ulcers of diabetic with exogenous NGF or in combination with
an anti-NGF Ab. Wound healing was accelerated with exogenous NGF, but
these effects were completely abolished with pretreatment with the anti-NGF
antibody (Matsuda et al., 1998). Clinically, exogenous application of NGF to nonhealing diabetic ulcers have shown slow (5-14 weeks), but positive effects in 15
patients with leg or foot ulcers (Aloe et al., 2008). This represents an interesting
new treatment whose mechanism is yet to be revealed.
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Receptor tyrosine kinase ligands produced by other cell types but affecting
reepithelialization include insulin-like growth factor (IGF) and fibroblast growth
factor (FGF). Produced by bone marrow stem cells (IGF) and fibroblasts (FGF),
these paracrine growth factors activate their corresponding receptors found on
keratinocytes to enhance reepithelialization. Studies using gene deletion in mice
as well as looking at clinical patient samples indicate the importance of these two
growth factors in wound healing.
The insulin-like growth factor family is a group of ligands released during
wound healing. There are two known insulin-like growth factors (IGFs), IGF-I
and IGF-II. Both IGFs bind to the type I IGF receptor, while IGF-II can also bind
to the IGF type II/mannose-6 phosphate receptor. IGF-I was present in wound
fluid in both a porcine and rat model (Steenfos and Jansson, 1992; Marikovsky et
al., 1996), and both mRNA levels (Steenfos and Jansson, 1992) and protein
levels (Todorovic et al., 2008) of IGF-I were elevated in wounded skin of rats.
Both IGF-I and IGF-II mRNA expression occured in porcine wounded and
unwounded epithelium (Antoniades et al., 1993). In chronic non-healing wound
models using the glucocorticoid stimulated diabetes model, mRNA and protein
levels of both IGF-I and IGF-II were decreased, indicating the importance of
these molecules to diabetic wound healing (Brown et al., 1997). Clinically, in
diabetic patient samples, IGF-I levels were decreased as compared to healthy
skin (Blakytny et al., 2000). Using a transgeneic mouse with the IGF-1 gene
under the keratin 14 promoter to overexpress IGF-1 in the skin revealed that IGF1 accelerated reepithelialization (Semenova et al., 2008). Recently, investigators
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discovered that bone marrow stem cells enhanced wound closure, produced 49
fold higher levels of IGF-1mRNA, and released 22 fold higher levels of IGF-1
protein into the conditioned medium than dermal fibroblasts (Chen et al., 2008).
Although the exact mechanisim of wound closure is as of yet unknown, IGF from
bone marrow stem cells represents yet another growth factor able to enhance
wound healing and stresses the importance of IGF-1 in normal wound healing,
especially in chronic wounds.
Fibroblast growth factors (FGF) stimulate pathways in the developing
embryo as well as adult tissues (Grose and Werner, 2004). The FGF family is
very complex, with 4 FGF receptors (FGFR1-4), 3 of which have splice variants,
and over 22 FGFs (Werner and Grose, 2003). In wound healing of adult tissues,
the major role of FGF is to mediate angiogenesis (Grose and Werner, 2004) and
were found to be upregulated at day 1 post wounding (Bhora et al., 1995). One
FGF family member, FGF-2, is important in reepithelialization, as FGF-2 null
mice showed delayed wound healing (Grose and Werner, 2004). This finding
was limited to FGF-2, because FGF-1 null mice exhibited normal wound healing,
and FGF-1/FGF-2 double mutants had similar wound defects as FGF-2 null mice.
In excisional wound models, mRNA levels of several FGFs were upregulated,
including FGF-1, FGF-2, FGF-5 and FGF-7 (Werner and Grose, 2003). Protein
levels of FGF-2 have also been reported to be upregulated in murine, porcine
and human wound models (Werner and Grose, 2003).
One FGF member, keratinocyte growth factor (KGF), also known as FGF-7,
has been well studied in wound healing. KGF works in a paracrine fashion,
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released by fibroblasts and binding to its receptor, FGF2IIb, on neighboring
keratinocytes in response to wounding (Werner et al., 2007). In mouse studies,
KGF upregulation at both the protein and mRNA level occurred at the wound
margin as early as 1 day post wounding (Grose and Werner, 2004). FGF2IIb
receptor null mice showed a marked delay in wound healing, however, in KGF
null mice, wound healing was normal (Guo et al., 1996). One explanation for this
could be that additional FGF ligands bound the FGF2IIb receptor, namely FGF10 (KGF-2), and the newly discovered FGF-22. FGF-10 expression remains
controversial in the literature, as one group found increased mRNA levels
whereas another found no change in response to wounding in mice (Werner et
al., 2007). FGF-22 binds to the FGF2IIb receptor, although FGF-22 is expressed
mainly by keratinocytes, which is an example of autocrine activation as opposed
to the paracrine response elicited by FGF-7 (Werner et al., 2007). Clearly, the
FGF family of ligands and receptors has many roles in wound healing that
warrant further investigation.
There are several growth factors produced and released in response to a
wound. HGF, VEGF, NGF, and PDGF are produced by keratinocytes, and act to
promote granulation tissue formation, angiogenesis, keratinocyte proliferation
and dermal contraction, respectively. FGFs and IGFs are produced by fibroblasts
and bone marrow cells and enhance angiogenesis and enhance wound closure.
Collectively, ligands for receptor tyrosine kinases regulate nearly all aspects of
wound repair.
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Figure 1.4.1
Receptor Tyrosine Kinase Families
Several receptor tyrosine kinases play roles in wound healing. Ligands are produced by
keratinocytes as well as other cell types. Ligands work in both an autocrine and paracrine
fashion to execute beneficial effects during several major events of wound healing, including
granulation tissue formation, angiogenesis, and reepithelialization.
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1.5 The EGF Receptor and Ligands in Wound Repair
Another large family of ligands and receptors are those of the epidermal
growth factor (EGF) family (Figure 1.5.1). The EGF receptor is a receptor
tyrosine kinase that plays pivotal roles in autocrine regulation of keratinocyte
proliferation and migration. Several studies have focused on the effects of the
EGF receptor family and ligands on healing.
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Figure 1.5.1
EGFR and Associated Ligands in Wound Repair
There are 4 EGFR family members EGFR (HER1),ErbB2 (HER2), ErbB3 (HER3), ErbB4 (HER4).
EGFR is the first member of the family discovered. ErbB2 cannot bind ligand, but can signal
once it forms a dimer with another family partner. ErbB3 cannot signal, but can bind to a ligand
and partner with another family member to transduce signal. ErbB4 is not usually found in
keratinocytes. Ligands include EGF, TGF-α, HB-EGF, epiregulin, amphiregulin, beta-cellulin, and
epigen.
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1.5.1

EGF receptor ligands

There are seven known ligands for the EGF receptor (EGFR), EGF,
transforming growth factor alpha (TGF-α), heparin bound EGF (HB-EGF),
epiregulin, amphiregulin, beta-cellulin and epigen (Schneider et al., 2008) (Figure
1.5.1). Of these EGFR ligands, several have been studied in wound healing,
and will be discussed further, namely, epiregulin, TGF-α, HB-EGF, and EGF. It
is important to note the other EGFR ligands (beta-cellulin, amphiregulin, and
epigen) are mitogenic in different systems, and could possibly play a role in
wound healing (Schneider et al., 2008). The EGFR family of ligands can act on
several EGF receptors, named EGFR (also known as ErbB1 or HER1), erbB2
(HER2), erbB3 (HER3) and erbB4 (HER4) (Figure 1.5.1). Upon ligand binding,
the receptors homodimerize or heterodimerize and then are internalized. ErbB2
has no known ligand, but can participate in signaling via heterodimerizing with
other erbB receptors. ErbB3 cannot phosphorylate, due to an inactive kinase
domain, but like erbB2, can participate in signaling by forming heterodimers with
one of the other EGFR family members. ErbB4 is either present in very low
levels or is undetectable in both human and murine epidermis (Plowman et al.,
1993; Xian et al., 1997; Kiguchi et al., 2000).
1.5.1.a

Animal Studies with EGF

Epidermal growth factor (EGF) is the first discovered and most extensively
studied ligand of the EGFR. It was reported in 1962 by Dr. Stanley Cohen that a
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factor present in the submaxillary gland of mice, once purified caused early
eyelid opening and tooth eruption when injected daily into newborn mice (Cohen,
1962). During the first stage of wound healing, EGF is released by platelets into
the wound area, and can also be produced by monocytes, macrophages and
keratinocytes (Clark, 1988). EGF as well as other EGFR ligands such as HBEGF and TGF-α were present in high concentrations in the wound fluid of rats,
humans and pigs (Grotendorst et al., 1989; Ono et al., 1995; Marikovsky et al.,
1996).
Several studies have looked at the effects of exogenous EGF application in
wound healing. Even though the methods of EGF delivery differ, wound healing
is improved with exogenous applications of EGF with an increased rate in some
aspect of wound repair reported in most cases.
One of the earliest studies of wound repair with EGF used circular punch
biopsies on rabbit ears (Franklin and Lynch, 1979). It was a qualitative report of
quicker wound healing with EGF treated as compared to control. Histologically,
EGF treated epithelium was thicker and had more mature connective tissue than
control wounds. Another parameter of wound repair is tensile strength of the
epidermis once it has undergone reepithelialization. Tensile strength was 3
times greater with liposome encapsulated EGF 14 days post treatment as
compared to saline or liposome alone treated wounds (Brown et al., 1988).
Using a gelatin film to protect EGF from proteolytic degradation in partial
thickness canine wounds, reepithelialization of the wound area was greater than
50% by 9 days, which was statistically greater than control (Tanaka et al., 2005).
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Gelatin sponges with EGF loaded microspheres also showed a marked increase
in reepithelialization by 7 days post wounding via punch biopsy in the dorsal area
of rabbit skin (Ulubayram et al., 2001).
The above mentioned studies used mice, rats, rabbits and dogs, which
have loose skin that contains a panniculus carnosus, a thin sheet of striated
muscle. Wound healing in these animals occured mostly by wound contraction
of the dermis rather than reepithelialization (Arnoux, 2005). Porcine skin, like
human skin, is an example of tight skin that lacks a panniculus carnosus. Wound
healing of tight skin relies heavily on reepithelialization for wound closure.
Two studies found that 10 μg/mL EGF significantly improved wound closure
as compared to control (Nanney, 1990) or as compared to vehicle alone (Brown
et al., 1986) in partial thickness porcine wounds. However, a single treatment of
EGF at 10 μg/mL was not effective, indicating the necessity of daily treatment in
these studies. In addition to an increased rate of closure, keratinocyte
differentiation was also improved with the appearance of a cornified layer only 5
days post injury (Nanney, 1990). Overexpression of EGF in porcine
keratinocytes accelerated reepithelialization of full thickness skin wounds as
compared to control skin (Vranckx et al., 2007). In summary, several animal
models have been used to evaluate the effects of elevated EGF via different
delivery methods, all with positive results suggesting clinical benefit for human
wound healing.
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1.5.1.b

Human Studies with EGF

In general, human studies are in agreement with animal models. One
indication that EGF rather than other growth factors may provide benefit was
provided in a study to measure keratinocyte outgrowth from human skin punch
biopsies. The greatest amount of keratinocyte proliferation and epidermal
outgrowth occurred following treatment with EGF when compared to IGF or FGF
(Bhora et al., 1995).
Clinically, wound healing is improved in patients treated topically with EGF.
Silver sulfadiazine cream alone is known to accelerate wound healing when
applied daily, but the addition of EGF accelerated the healing to a greater extent
when compared to matched skin graft donor sites in a 12 patient double blind
study (Brown et al., 1989). However, a study of 44 patients with chronic venous
ulcers failed to show a statistically significant improvement with EGF treatment
over placebo in a double blind clinical trial (Falanga et al., 1992). These data
taken together suggest that there may be differences between wound healing in
acute and chronic disease states. Chronic wounds represent a greater health
threat to patients, and several additional studies have taken this into account and
studied the impact of EGF on treatment of diabetic foot ulcers.
One of the first clinical studies of EGF treatment for chronic wounds
occurred in a 2003 study of 61 patients with diabetic foot ulcers. Ulcer grade was
determined and patients with grade I or grade II were accepted into the study
(Tsang et al., 2003). Patients received either Actovegin alone, a cream made
with protein free calf blood extract purported to promote uptake of nutrients into

38

the wound, or Actovegin in combination with either 0.02% or 0.04% EGF (Tsang
et al., 2003). After 12 weeks, the 0.04% EGF group had a rate of healing greater
than placebo alone, and this finding was statistically significant. Out of the 21
patients in the 0.04% group, 20 patients achieved full healing after 12 weeks.
The 0.02% EGF group did not achieve healing greater than with placebo alone.
A recent study used an advanced moist dressing alone or in combination with
EGF on a total of 89 patients with diabetic foot ulcers and 76% of wounds healed
with the advanced dressing (Hong et al., 2006). While the Tsang study limited
the patients to a severity of grade II, Hong et al. allowed both grade II and grade
III patients in this trial. Of the combined grade II and grade III cases, 24%
improved with advanced dressing alone; while 58% of the total cases improved
with the advanced dressing containing 0.001% EGF (Hong et al., 2006). A
Phase III study was conducted in India with the use of REGEN-D (150 μg/g
recombinant EGF), and the results were compared to a post-marketing follow up
study with the same medication 2 years later (Mohan, 2007). A total of 135
patients with grade I and II lesions were assessed. The post marketing study
found that 92% of patients achieved full wound closure by week 10, as compared
to 69% at the same timepoint in the Phase III study, which had a smaller sample
size of 60 subjects. The investigators stressed that the results demonstrated the
efficacy of the product. Intralesional injections of Citoprot-P (recombinant EGF;
available as either 25 μg/mL or 5 μg/mL) were given as 5 mL injections to
patients with either grade III or grade IV ulcers, and at serious risk for foot
amputation. After 5 weeks, 74% of the 25 μg/mL treatment group achieved a
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complete response, which was defined as coverage of the ulcer surface with
granulation tissue and 50% of the 5 μg/mL treatment group achieved a complete
response. These response numbers increased to 83% and 61%, respectively
after 8 weeks.
Collectively, there is good experimental and clinical data for the use of EGF
in both acute and chronic wounds. Studies that started in the early 1990’s in
animal models have led to successful clinical trials in less than 20 years. As the
delivery systems become more sophisticated, advances in wound care will
continue to provide better treatment for future patients.

1.5.2

Other EGFR ligands in wound repair

EGF is not the only ligand for EGFR, and it stands to reason that the other
ligands can also contribute to wound repair. Since the discovery of EGF and its
benefits in wound repair, other EGFR ligands have been investigated for their
benefits to wound repair. Examples of ligands that positively affect wound
healing include epiregulin, TGF-α, and HB-EGF.
Epiregulin (EPR) is a member of the EGF family of growth factors with 2450% homology to other EGF ligands (Draper et al., 2003b). Although the EPR
protein levels are low in the skin, 2.5 fold upregulation of EPR mRNA occurred
after wounding normal mouse keratinocytes, but only 1.5 fold upregulation
occurred in human keratinocytes (Shirakata et al., 2005). Topical application of
EPR significantly improved healing of murine excisional wounds, as compared to
control and EGF treated animals (Draper et al., 2003b). Further studies from this
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group extended the findings to show that EPR accelerated wound repair more
effectively than either TGF-α or EGF (Draper et al., 2003a). However, EPR null
mice showed no defects in wound healing (Schneider et al., 2008), so the
functional importance of epiregulin in wound healing is still unclear. It is possible
that other EGFR ligands were able to compensate for the lack of epiregulin in the
epidermis.
TGF-α is a growth factor that is upregulated in wound tissue soon after
injury (Grose and Werner, 2004). TGF-α is expressed in several layers of the
epidermis, including the basal, spinous and granular layers (Schneider et al.,
2008) and was found in wound fluid of rats (Grotendorst et al., 1989). During
wound healing, TGF-α is released from platelets during the clotting phase, and
macrophages produce TGF-α during the inflammatory phase (Clark, 1988),
suggesting that TGF-α release is important during early stages of wound healing.
Exogenous application of TGF-α enhanced reepithelialization of burn wounds in
pigs. In this study, a statistically significant increase of reepithelialization
occurred with 0.1μg/mL TGF-α as compared to placebo or the same
concentration of EGF, although earlier papers determined that the optimal
concentration of EGF to be 10μg/mL (Schultz et al., 1987).
Two groups looked at the effect of the loss of TGF-α in wound repair in the
early 90’s. Luetteke et. al. used the waved-1 mice, which have a genetic mutation
in the TGF-α gene, and were first described in 1933 by Frances A.E. Crew
(Schneider et al., 2008). Mann et. al. deleted the TGF-α gene and studied the
effects of wound healing in these mice. In both cases, very similar phenotypes
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were described, including curly whiskers and hair, as well as corneal defects
(Luetteke et al., 1993; Mann et al., 1993). Both sets of investigators saw no
change in wound healing with the TGF-α deficient mice as compared to
heterozygous or wild type controls. Mann et al. looked at homozygous null mice
as compared to heterozygous mice, and found no change when observing
wound healing of clipped tails. Luetteke et al. used two different methods, a full
thickness excision in the backskin as well as punch biopsy of the ear and saw no
change in healing in the homozygous null mice as compared to wild type
controls. Investigators concluded that EGF or some other EGFR ligand could be
compensating for the lack of TGF-α in these models.
TGF-α null mice show no difference in wound healing in earlier studies, but
a more recent study found a large decrease in reepithelialization of partial
thickness ear wounds 3 days post wounding as compared to control mice (Kim et
al., 2001). This statistically significant reduction in reepithelialization was
extended to day 5 post wounding, yet healing of wounds in both sets of animals
was complete by 8 days. Ear wounding solely requires reepithelialization, and no
granulation tissue formation. In order to study the effects of granulation tissue,
wound healing from a head wound, which requires both reepithelialization and
granulation tissue formation was performed. There were no differences in the
rate of reepithelialization in the head wounds from TGF-α null mice and the
control mice. The authors of this study concluded that the formation of
granulation tissue compensated for the lack of TGF-α in the full thickness model
in their experiments and the previous reported experiments. TGF-α is also found
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at the leading edge of migrating epithelium in human burn patient samples
(Wenczak and Nanney, 1993), indicating the importance of this ligand in human
reepithelialization.
Heparin bound EGF (HB-EGF) is another EGFR ligand that is present in
wound fluid (Marikovsky et al., 1996; McCarthy et al., 1996) and protein
expression was found in keratinocytes at the wound margin of burn patients
(McCarthy et al., 1996). In normal skin, HB-EGF is found in hair follicle epithelial
cells and in proliferating keratinocytes. Both mRNA and protein levels of HBEGF increased at the leading edge of in vitro and in vivo wounds (Shirakata et
al., 2005; Mathay et al., 2008). The use of CRM197, an HB-EGF inhibitor,
inhibited in vitro wound healing in a human corneal epithelial cell line (Boucher et
al., 2007). HB-EGF null mice died postnatally due to heart defects (Schneider et
al., 2008). However, a conditional mutant mouse strain was generated that
limited the gene deletion to keratinocytes, and in these mice, reepithelialization,
and specifically keratinocyte migration independent of proliferation, was impaired
(Shirakata et al., 2005).
Looking at the similarities in EGFR ligands with respect to their
enhancement of wound healing suggests a functional redundancy, however,
differences in function could be due to timing of expression during wound
healing. While TGF-α expression occurs at the onset of wounding, EPR and HBEGF occured at later timepoints. Differences in wound healing models make it
difficult to draw conclusions between studies on the exact roles of each EGFR
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ligand, but it is clear that collectively EGFR ligands contribute to the
reepithelialization phase of wound repair.

1.5.3

EGFR in wound repair
Numerous EGFR ligands are present in wound fluid, suggesting that

EGFR plays an important part in wound healing. Transactivation of EGFR is an
alternate method of stimulating a response without ligand, and examples of this
can be found in wound healing. Several factors have been shown to
transactivate the EGFR, and these include pathways stimulated by G protein
coupled receptors (GPCRs) (Filardo, 2002; Yahata et al., 2006), cytokines
(Tanida et al., 2004; Itoh et al., 2005), antimicrobial peptides (Tokumaru et al.,
2005; Carretero et al., 2008), crosstalk by other tyrosine kinases (Higashiyama
and Nanba, 2005; Xu et al., 2006; Xu and Yu, 2007; Nanba et al., 2008),
nucleotides (Boucher et al., 2007) and extracellular matrix components (Cabodi
et al., 2004; Tran et al., 2004). These examples represent the large variety of
non ligands that researchers have found to cause transactivation of the EGFR.
Many of these factors transactivate the EGFR by inducing shedding of HB-EGF,
which in turn activates the EGFR. Non-ligand transactivation of the EGFR
pathway can occur by other factors present during wound healing, including
angiotensin II, catecholamines, and inflammatory markers TNF-α and IFN-γ
(Pastore et al., 2008). These studies highlight the importance of the wound
milieu and the ability of non EGF ligands to cause stimulation of the EGFR
pathway.
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There are several mechanisms for activation of the EGFR, including ligand
and non-ligand activation that lead to enhanced wound repair. There is also
evidence that levels of EGFR have an impact on wound healing. Tape stripping
induces a wound that is limited to the epidermis, and using this protocol a
maximum of 5 fold increase in the levels of the EGFR receptor was seen from 1
to 2 days post wounding at the margins of healing wounds that returned to
baseline levels after day 4 post wounding (Stoscheck et al., 1992). This same
group of investigators extended their focus to EGFR in in vivo wounds. In
patients with either partial thickness or full thickness burns, upregulation of EGFR
was seen in the advancing epithelium adjacent to the burn (Wenczak et al.,
1992). This upregulation was limited to the keratinocytes, as the underlying
dermis showed no EGFR staining.
Further evidence for the importance of the EGFR in wound healing is
revealed by EGFR null mice. Although EGFR null mice do not live more than a
few days after birth (Threadgill et al., 1995), skin from these newborns can be
grafted onto adult mice to study the impact of EGFR on wound healing. Wound
healing was defective in EGFR null skin (Repertinger et al., 2004). Whereas
wound healing was complete within 5 days in wild type skin grafts, repair of
EGFR null skin took up to 14 days to complete (Repertinger et al., 2004).
Conversely, overexpression of the EGFR by gene gun transfection increased
wound healing in a porcine skin model (Nanney et al., 2000). In our laboratory,
we have shown keratinocyte cell motility increased with increased EGFR
activation (McCawley et al., 1997).
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Most studies have focused on the contributions of the EGFR on wound
repair. Recently, the ErbB3 receptor was implicated in wound healing. In a
porcine wound model, partial thickness wounds were created, and adenovirus
with ErbB3 gene was deposited in the wound bed (Okwueze et al., 2007).
Various EGFR ligands (EGF, HB-EGF, epiregulin, or heregulin) were then added
in a gel matrix once daily. Significant increases in reepithelialization occurred
with all ligands in wounds with elevated ErbB3 as compared to the LacZ
adenovirus control. However, ligand alone also caused an increase in
reepithelialization, and the only combination of ErbB3 and ligand to cause a
statistical increase over ligand alone was HB-EGF and ErbB3, indicating
involvement of the EGFR in a EGFR:ErbB3 heterodimer because HB-EGF does
not bind to ErbB3. The activity of ErbB3 in wound healing represents an exciting
new area of research that has previously gone unstudied.
Regulation of both ligands for the EGFR and the levels of receptor itself
appear to be important for reepithelialization. Expression levels must be
appropriate, as disruption of receptor levels delays wound repair, as seen in the
null receptor studies. It is possible that several different mechanisms for both
direct activation and transactivation exist in order to regulate appropriate
expression during wound healing. Further studies on the different receptor family
members and their coordinate activation during wound healing could represent
an interesting avenue for enhancing wound repair.
Little is known about the essential processes regulated by the EGFR that
may be critical for wound repair, but in order to migrate during reepithelialization,
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keratinocytes must detach from neighboring cells, which requires the cells to lose
or modify their adhesive properties and obtain migratory properties. The loss of
these adhesive properties includes cell-cell junctions, such as adherens junctions
and desmosomes as well as cell-matrix interactions. The cell must also loosen
its adhesion to the extracellular matrix below in order to migrate. These activities
are very similar to what happens in epithelial to mesenchymal transition (EMT),
which is important in the developing embryo and is major event for metastasis in
cancer.

1.6 Epithelial to mesenchymal transition (EMT)
Epithelial to mesenchymal transition (EMT) is a process in which epithelial
cells undergo profound changes to resemble a mesenchymal cell type. Classical
EMT was first studied in embryonic development, and occurs as epithelial cells
take on a migratory fibroblastic like phenotype and are capable of invading
extracellular matrix (ECM). Developmental EMT occurs in two phases of
development, gastrulation and migration of the neural crest cells from the neural
tube (Hay, 2005). Gastrulation is the migration of the primitive endoderm cells
(epithelial origin) to invaginate within the egg cylinder and become mesodermal
mesenchymal cells (Thiery, 2002). Once this process is complete,
organogenesis begins.
In vertebrates, neural crest cells are those epithelial cells that are at the
border of the neural tube and the epithelial ectoderm (Newgreen, 2005). These
cells migrate from the neural crest and are the precursors to an entire subset of
cell lineages that exist throughout the body, from connective tissue to skin
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pigment cells (Newgreen, 2005). Developmental EMT is characterized by
changes in gene expression that serve as a molecular definition of the process.

1.6.1

Classical Hallmarks of EMT
A switch from keratin to vimentin based intermediate filaments and the

loss of cell-cell junctions are two markers that are traditionally used to define an
EMT event (Thiery, 2003). The application of these markers to define EMT in
adult tissue, such as a full EMT in tumor metastasis or a partial EMT in wound
repair is still controversial. However, a switch from keratins to vimentin, an
appearance of stress fibers, a loss of E-cadherin, and a gain of N-cadherin are a
few of these classical hallmarks that are widely accepted to indicate EMT in
normal and tumorigenic adult tissues.
When cells take on a mesenchymal phenotype, in general, they assume a
biopolar, spindle shaped morphology. The cells extend filopodia from the front,
leading end, and are able to invade neighboring extracellular matrix (ECM). One
switch that may help these cells become more invasive is the switch from a
keratin based cytoskeleton to a vimentin based cytoskeleton. Increased vimentin
is common in highly invasive tumor cells (Heatley et al., 1993; Gilles et al., 1996;
Zajchowski et al., 2001), and there is experimental evidence that vimentin
expression fosters increased migration (Ramaekers et al., 1989; Gilles et al.,
1999; McInroy and Maatta, 2007). In contrast, although there is some evidence
for increased vimentin at wound margins (Brem et al., 2007), dramatic changes
in keratin profiles are evident in reepithelialization.

48

Upon injury, keratinocytes change their keratin profile again in a process
called the keratinocyte activation cycle. During this cycle, IL-1 initiates activation
of keratinocytes and expression K6, K16 and K17 (Freedberg et al., 2001). The
most well studied activator of keratinocytes is the EGF receptor. EGFR
activation upregulated both K6 and K16 expression (Jiang et al., 1993).
Deactivation of keratinocytes is achieved by TGF-ß expression from dermal
fibroblasts once reepithelialization is complete (Freedberg et al., 2001). This
switch of keratin profile after wounding is very similar to the cytoskeletal switch
that other cell types undergo during a full EMT.
Another well studied classical marker of EMT is the loss of cell-cell
junctions. The mechanisms of cell-cell junction disruption, including the events
that occur during EMT, will be discussed in detail in section 1.7.1. There is a
striking similarity between mechanisms of migration by cells in development, and
wound repair, although reepithelialization appears to represent a partial EMT.

1.7 Cell-cell junctions
Disruption of cell-cell junctions is a hallmark of EMT. Keratinocytes
maintain their integrity by forming cell-cell contacts with neighboring cells. There
are three types of cell-cell contacts between cells: tight junctions, adherens
junctions and desmosomes.
Tight junctions form a seal around cells and prevent the passage of small
molecules through the epithelial barrier. This also functions as a way to separate
the basal from apical membrane proteins, thus regulating polarity (Tsukita et al.,
2008). Tight junction membrane proteins that directly mediate adhesion are
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claudin and occludin, which form a network of ridges (Figure 1.7.1, part A).
Intracellularly, they bind scaffolding zonula occludens proteins (ZO1-3), which
connect to the cytoskeleton via actin.
Adherens junctions are calcium dependent junctions that the most well
studied of all cell-cell junctions. Adherens junctions are comprised of several
proteins, including cadherins and catenins. E-cadherin is a calcium dependent
cell surface protein with intracellular and extracellular domains. The extracellular
domains interact with E-cadherin on neighboring cells, thereby creating adhesion
between cells (Figure 1.7.1, part B). ß-catenin binds to the intracellular domain
of E-cadherin and along with other scaffolding proteins, stabilizes the junction to
the actin cytoskeleton. ß-catenin can also function in the Wnt signaling pathway.
Plakoglobin (γ-catenin) is analogous to ß-catenin in its scaffolding function, and
can participate in adherens junctions as well as in desmosomes. Plakoglobin,
however, is a minor member of adherens junctions and is found preferentially in
desmosomes. It is currently unknown if plakoglobin can participate in signaling
pathways. Another adherens junctional protein is p120, which can bind to the
intracellular domain of E-cadherin, and like ß-catenin and plakoglobin, can enter
the nucleus, bind and regulate the transcriptional partner Kaiso, although it is still
unknown if it can act as a transcriptional activator on its own (Daniel, 2007) .
Alpha-catenin can bind to either ß-catenin and plakoglobin, and connects the
adherens junction to the cytoskeleton by binding to actin.
Desmosomal structure is similar to adherens junctions. The adhesion
molecules in desmosomes that mediate intercellular adhesion are also
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cadherins, named desmoglein and desmocollin (Chitaev and Troyanovsky, 1997)
(Figure 1.7.1, part C). Scaffolding proteins of desmosomes include the
aforementioned plakoglobin, as well as desmosomal specific scaffolding proteins
desmoplakin and plakophilin. The final attachment intracellularly of desmosomes
is plakophilin to intermediate filaments, connecting the desmosome to the
cytokeratin network and stabilizing the complex. Desmosomes are very
abundant in skin epithelial cells, and it is from the abundance of keratin that the
cells get their alternate name, keratinocytes.
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Figure 1.7.1
Cell-cell Junctions
A. Tight junctions function in polarity and to keep the skin impervious to water. Occludin and
claudin are the two proteins that form dimers across cells, and bind ZO family members
intracellularly, which then form a stable connection to the actin cytoskeleton.
B. Adherens junctions also use the actin cytoskeleton for stabilization, adhesion to which is
mediated by α-catenin. Other adaptor proteins include p120, ß-catenin, and plakoglobin, which
bind the transmembrane protein E-cadherin, which mediates cell-cell adhesion across cells by
forming a homodimer with E-cadherin from neighboring cells.
C. Desmosomes, the predominant cell-cell junction in keratinocytes, have their own desmosomal
cadherins, desmoglein and desmocollin, which form heterodimers across neighboring cells.
Intracellularly, they bind plakoglobin, plakophilin, and desmoplakin, which attach to intermediate
filaments for junctional stabilization.
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1.7.1

Cell-cell junctions in EMT
Cell-cell junctional modulation occurs during formation of the primitive

streak in development and in invasive carcinomas. Downregulation of junctions
also occurs during wound healing, and will be discussed in section 1.7.2.
During development, in particular gastrulation, cells migrate and start to
form the primitive streak. The primitive streak is the linear area at which the
epiblast undergoes EMT activity to form mesenchyme and endoderm under the
epithelial cells that remain to form the outlying ectoderm (Hay, 2005). At this
point, cells migrating into the primitive streak have no desmosomes but extensive
tight junctions (Shook and Keller, 2003). Once cells migrate into the primitive
streak, desmosomes are detected as evidenced by staining for desmoplakin on
the periphery but not throughout the streak (Franke et al., 1982). The adherens
junction protein E-cadherin is also lost at the primitive streak (Damjanov et al.,
1986), in a process that has recently been found to be dependent on FGF
signaling (Ciruna and Rossant, 2001). The loss of this E-cadherin alone is
sufficient to induce many of the changes associated with EMT (Baum et al.,
2008).
The adherens junction cadherin E-cadherin has been extensively studied
for its role in tumor-associated EMT. A inverse relationship between E-cadherin
expression and tumor invasiveness has been established in experimental
systems and tumor tissues (Jeanes et al., 2008), although there are notable
exceptions. E-cadherin and N-cadherin are maintained in well differentiated
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ovarian cancers, and a increase in tumor invasiveness correlates with a loss of
E-cadherin but not of N-cadherin (Hudson et al., 2008). In breast cancer tumor
lymphovascular emboli, there is an increase in E-cadherin that allows the tumor
to persist in the lymphovasculature, and the tumor can be eliminated with the use
of anti-E-cadherin antibodies (Tomlinson et al., 2001). However, there is also a
strong correlation between loss of E-cadherin and higher cancer grade and
metastasis in cancers of the head and neck (Kramer et al., 2005), bladder
(Baumgart et al., 2007), breast (Heimann et al., 2000), gastric tissue (Mayer et
al., 1993), nasopharyngeal tissue (Zheng et al., 1999), ovary (Davidson et al.,
2000), pancreas (von Burstin et al., 2009), prostate (Mol et al., 2007) ,and
colorectal tissue (Delektorskaya et al., 2005).
Although less well studied, there is also evidence for downregulation of
desmosomes in invasive tumors. Interestingly, the modulation of desmosomes in
cancer has been investigated sporadically since the early 1980’s as a possible
tumor marker in not only skin cancer, but other epithelial cancers as well. Early
studies looked at total desmosome numbers in carcinomas by using electron
microscopy. A reduced number of desmosomes were reported in several
invasive carcinomas (Pauli et al., 1978; Alroy et al., 1981; Kocher et al., 1981;
Schindler et al., 1982), although one group reported that the desmosomes that
remained were larger and occupied a larger amount of cell surface area (Pauli et
al., 1978). A later study used rat bladder carcinoma cells that normally had an
epithelial phenotype but could be induced to an EMT fibroblast phenotype with
the addition of “inducing medium”. This study found the internalization (or
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abnormal expression) of desmoglein, desmoplakin, and plakoglobin upon
inducing conditions, as well as increased migratory activity, although the
migratory capabilities were not dependent on the internalization of desmosomes
(Boyer et al., 1989). This suggests that downregulation of desmosomes may be
associated with EMT-like events.
The downregulation of cell-cell junctions, along with the rearrangement of
the cytoskeleton and change in morphology from a stationary epithelial cell to a
migratory mesenchymal like cell that occurs during EMT is very similar to what
happens at the leading edge of a wound, Indeed, a partial EMT iis essential for
reepithelialization, as well as the reversion back to an epithelial phenotype once
reepithelialization is complete.

1.7.2

Cell-cell junctions in wound healing
The dissolution of both hemidesmosomes, which connect the cell to the

extracellular matrix, and desmosomes (Krawczyk and Wilgram, 1973; Sciubba et
al., 1978) is a key step in wound healing. The Krawczyk and Wilgram study
followed keratinocytes after suction induced blister wounding in mice for 12 to 18
hours and found the restoration of both hemidesmosomes and desmosomes
during reepithelialization occurs in several steps. First, the appearance of fibrils
that connect the keratinocytes, which we now know are cadherins. Second, the
attachment plate develops at the inner leaflet of the membrane. We can propose
that this is the assembly of the rest of the junctional components. Finally,
tonofilaments insert into the attachment plate, which we now call intermediate
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filaments, attaching to the intracellular junctional proteins. This three stage
process held true for both desmosomes, which maintain cell-cell attachments,
and hemidesmosomes, which attach cells to the basement membrane. Scuibba
and coworkers extended this finding in rats, comparing the healing of oral
mucosa, which is known to heal very rapidly, to the healing of epidermis (Sciubba
et al., 1978). In this case, hemidesmosomes followed the same formation
sequence as in the Krawczyk and Wilgam study, but occurred by 4 hours in
mucosa as compared to 12 hours in rat epidermis. Additional studies in rabbit
skin saw a decrease in the number of desmosomes and intermediate filaments at
the wound margin 8 days post wounding as compared to control skin, and at 10
days post wounding, intermediate filaments were still retracted away from the
plasma membrane (Gabbiani et al., 1978). The reappearance of desmosomes is
now considered a marker of the end of reepithelialization.
Adherens junctions are intimately linked to desmosomes in that their
formation precedes desmosome assembly (Lewis et al., 1997). In mouse
epidermis, a decrease in E-cadherin was seen at day 3 post wounding in both full
thickness incisional or excisonal type wound model. E-cadherin expression was
restored at day 5 in the incisional model but took up to 10 days in the excisional
model (Kuwahara et al., 2001). Antibody blocking studies show that functionally
blocking E-cadherin led to uneven wound margin and disruption of the
reorganizing actin cytoskeleton in mouse epidermis (Danjo and Gipson, 1998). A
decrease in E-cadherin staining was detected at the migrating corneal epithelia in
a canine eye wound model (Chandler et al., 2007). In contrast, E-cadherin was
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apparent within all epithelial cells throughout reepithelialization in a rat corneal
wound healing model (Suzuki et al., 2000). Desmogleins-1 and -2, however, in
agreement with the earlier mentioned studies, were decreased immediately after
laser ablation and did not reappear until the basement membrane, as indicated
by laminin-1 staining, was reestablished (Suzuki et al., 2000).
In a rat corneal wound model, investigators observed tight junctions
throughout the 72 hour reepithelialization process and found that the tight
junction proteins occludin and ZO-1 were present in epithelial cells throughout all
stages of reepithelialization (Suzuki et al., 2000; Hutcheon et al., 2007). One
explanation for the maintenance of tight junctions throughout wound healing is to
serve as a scaffold for assembly and localization of myosin cables during wound
repair. Using Madin-Darby canine kidney (MDCK) epithelial cells, cells were
observed using live cell microscopy after laser ablation of the epithelial
monolayer and a continuous association between myosin and ZO-1 occurred as
quickly as 5 minutes post wounding (Tamada et al., 2007). In human epidermis,
the trend continued, as ZO-1 and occludin were present in migrating
keratinocytes 6 days post wounding (Malminen et al., 2003).
Clearly, cell-cell junctions undergo different fates during reepithelialization.
While tight junctions remain intact, adherens junctions and desmosomes are,
with the exception of a few cases, downregulated after the initial wound. The
mechanisms for this downregulation as of yet remain unclear, but candidate
mediators for this deregulation exist in the wound environment.
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1.7.3

Mechanisms of junctional modulation
There are several possible mechanisms within the wound environment for

junctional modulation. The decrease of divalent cations in the wound
environment, phosphorylation, proteolysis, internalization and transcriptional
repression are some of the reported processes for modulation cell-cell junctional
proteins (Figure 1.7.2).
Cadherins can only maintain adhesion in the presence of calcium. Normal
calcium levels (1.2-1.8 mM) are also necessary for proper keratinocyte
differentiation and stratification (Hennings et al., 1980; Boyce and Ham, 1983;
Hennings and Holbrook, 1983). Calcium levels in wound fluid is quickly
decreased at the onset of wounding, and remain low 24 hours post wounding
(Grzesiak and Pierschbacher, 1995). Restoration of normal calcium levels is
seen after 48 hours. Therefore, one well employed technique to study junctional
disruption is the removal of this divalent cation in the wound environment. Under
low calcium conditions (0.05-0.1 mM calcium), large intracellular spaces between
keratinocytes, a lack of desmosomes, and a retraction of intermediate filaments
from the cell border and their perinuclear accumulation was observed (Hennings
and Holbrook, 1983). Upon restoration of normal calcium levels in this system,
desmosomal plaques were visible as early as 5 minutes, and full desmosomes
were formed by 1-2 hours after calcium addition (Hennings and Holbrook, 1983).
Keratinocytes that were cultured and allowed to differentiate and stratify were
unable to migrate in a wound scratch assay (Magee et al., 1987). Once placed
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in low calcium conditions, a reduction in desmosomes occurred and the cells
were able to migrate (Magee et al., 1987).
E-cadherin mediated adhesion is also calcium dependent, so it stands to
reason that adherens junctions are also disrupted by low calcium conditions.
Indeed, vinculin and actin, two members of the actin cytoskeleton, were retracted
from the plasma membrane when cells are placed in low calcium, which could be
reversed as quickly as one hour after return to normal calcium levels (O'Keefe et
al., 1987). It is interesting to note that in this study, the appearance of
desmosomes was not visible until 2 hours after calcium restoration, indicating
that adherens junction reformation occurred before that of desmosomes. The
breakdown of adherens junctions with low calcium can be overcome by activation
of protein kinase C (PKC), indicating the importance of this signaling pathway in
adherens junction regulation (Lewis et al., 1994). Deletion studies revealed that
the formation of desmosomes required the preformation of adherens junctions
(Lewis et al., 1997).
Although tight junction adhesion molecules occludin and claudin are not
calcium dependent, tight junctions were also disrupted by calcium removal
(Rothen-Rutishauser et al., 2002). Experiments with antibodies against Ecadherin showed that the reformation of adherens junctions, desmosomes and
tight junctions with calcium addition were impaired when antibodies blocking Ecadherin were added (Gumbiner et al., 1988). During the initial phase of wound
healing, transient low levels of calcium could account for disruption of cell-cell
adhesion. However, calcium levels are restored to normal by 24 hours after
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wounding, while junctions remain downregulated, so other mechanisms must
account for this persistent downregulation.
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Figure 1.7.2
Multiple Mechanisms of Cadherin Disruption
There are multiple pathways that can lead to cadherin downregulation and junctional disruption.
Protein phosphoryation is one event that can cause quick dissociation from the cell-cell junctions.
Low calcium conditions can decrease adhesion, as these junctions are calcium dependent.
Proteolytic cleavage is an alternate mechanism to cause loss of adhesion and junction instability.
Internalization and trafficking of junctional proteins can also disrupt junctions, and finally,
transcriptional downregulation is a slow process to rid the cell of proteins necessary to build cellcell junctions
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1.7.3.a Protein phosphorylation
Another mechanism for junctional modulation is that of phosphorylation.
Several desmosomal and adherens junctional proteins are phosphorylated in
response to different stimuli (See Table 1.7.1). Phosphorylation of junctional
components occurs in junctional assembly and function, as several proteins,
once phosphorylated, cannot bind the necessary junctional partners. For
example, phosphorylation of ß-catenin and plakoglobin causes dissociation from
junctional complexes, where they can then participate in other pathways such as
transcriptional activation and/or repression (see section 1.7.3b). Phosphorylation
of ß-catenin increased migratory activity in in vitro wound assays that can be
inhibited with the addition of protein tyrosine phosphatases (Muller et al., 1999).
Addition of tyrosine phosphatases, as expected, reverted cells to an epithelial
phenotype and increased cell-cell adhesion (Taddei et al., 2002; Yan et al.,
2006).
Phosphorylation events also occur in tight junctions and regulates their
assembly and disassembly. Overexpression of Src revealed the persistence of
tight junctions but the absence of both adherens junctions and desmosomes
(Takeda and Tsukita, 1995). Src activation in MDCK cells causes tyrosine
phosphorylation of tight junction proteins occludin and claudin as well as the
adherens junction protein p120 (Palovuori et al., 2003). Ras transformed cells,
which have a fibroblastic phenotype and few cell-cell junctions were used to
study the effect of inhibition of the MAPK pathway on tight junctions. MAPK
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inhibition caused tyrosine phosphorylation of occludin and restoration of tight
junctions, indicating that this phosphorylation event participates in tight junction
assembly (Chen et al., 2000).
Phosphorylation is an acute signal in the wound environment that can
decrease adhesion between cells by targeting critical molecules through
phosphorylation and subsequent relocalization or degradation. Most junctional
proteins can undergo phosphorylation/desphosphorylation events, leading to
either junctional breakdown or stabilization. Regulation of assembly and
disassembly is essential in wound repair, so phosphorylation events are likely an
important in the reversible modulation of junctions that occurs during wound
repair.
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Table 1.7.1

Juntional Component Phosphorylation

Protein
Phosphorylation
Reference
Cadherins
E-cadherin
Tyrosine
(Fujita et al., 2002)
E-cadherin
Serine
(Serres et al., 2000)
Desmoglein-2
Tyrosine
(Lorch et al., 2004)
Linker proteins
ß-catenin
Tyrosine
(Kinch et al., 1995)
ß-catenin
Tyrosine
(Tyr-654)
(Piedra et al., 2001)
ß-catenin
Tyrosine
(Tyr-142)
(Piedra et al., 2003)
ß-catenin
Tyrosine
(Hu et al., 2001; Hu et al., 2003)
p120
Tyrosine
(Tyr-288)

Stimulus

Effect

Src, c-Met

Endocytosis

CK2

Stabilized junction

EGFR

Decreased junctions

Ras OE

E-cadherin dissociation

Mutants

E-cadherin dissociation

Ras OE

α-catenin dissociation

Phosophatase
inhihbitor

E-cadherin, α-catenin
dissociation, Nuclear localization

EGFR

Localized to
AJ,lamellopodia

(Mariner et al., 2004)
p120
Tyrosine
Src
Necessary for Shp-1 interaction
(Mariner et al., 2001)
p120
Serine
(Ser-879)
PDGFR
PKC dependent
(Brown et al., 2009)
Plakoglobin
Tyrosine
EGFR
Desmoplakin dissociation
(Tyr-692, Tyr-724, Tyr-729)
(Gaudry et al., 2001)
Plakoglobin
Tyrosine
EGFR
Junctional disruption
(Lorch et al., 2004; Yin et al., 2005)
Plakoglobin
Tyrosine
Phosphatase
E-cadherin, α-catenin
inhibitor
dissociation; Nuclear localization
(Hu et al., 2001; Hu et al., 2003)
Desmoplakin
Serine
TPA
Junctional disruption
(Amar et al., 1999)
Key: CK = OE= overexpressor, AJ = Adherens junctions, Shp-1: SH2 containing
nonreceptor tyrosine phosphatase, PKC = protein kinase C, TPA = 12-O-tetradecanoylphorbol13-acetate
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1.7.3.b Transcriptional regulation
Another mechanism for regulating cell-cell junctions is by transcriptional
repression, which is often seen in invasive cancers. The best studied example is
the transcriptional repression of the adherens junction protein E-cadherin. Ecadherin has several known transcriptional repressors, including Snail, E47,
Slug, SIP-1, deltaEF1 (ZEB1), ZEB2 and Twist (Bolos et al., 2003; Eger et al.,
2005; Peinado et al., 2007). Snail was one of the first transcription factors
discovered to directly bind E-boxes present in the E-cadherin promoter and
cause transcriptional repression (Batlle et al., 2000). Overexpression of Snail in
epithelial cells causes an invasive phenotype (Cano et al., 2000), and
introduction of siRNA against Snail in an invasive cell line restores E-cadherin at
cell-cell junctions (Batlle et al., 2000). Twist is a known developmental
transcription factor and is also upregulated in many cancers. Recently Twist was
found to mediate transcriptional downregulation of E-cadherin in several breast
cancer cell lines (Vesuna et al., 2008).
ZEB-2, (SIP-1) is another E-box binding transcription factor that overlaps
with the E-cadherin promoter area that Snail binds. ZEB-2 can be induced by
TGF-ß, and causes E-cadherin repression and increased invasion in MDCK cells
(Comijn et al., 2001). Another ZEB family member, ZEB-1 (δEF1) is upregulated
in response to Snail overexpression (Guaita et al., 2002), and can directly
repress E-cadherin and cause a EMT like phenotype (Eger et al., 2005).
Less is known about transcriptional repression of desmosomal cadherins
but a member of the Snail family of transcription factors Slug/Snai2 is one
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candidate. Slug/Snai2 was first discovered in development as being necessary
for neural crest development (Nieto et al., 1994; del Barrio and Nieto, 2002). It
also plays a role in EMT like responses in cancer development and wound repair.
Slug is necessary for reepithelialization during wound repair (Savagner et al.,
2005). Slug mRNA and protein levels are upregulated at wound margins in vivo,
ex vivo, and in vitro, along with a concomitant decrease in desmosomes as
evidenced by loss of desmoplakin (Savagner et al., 2005). Overexpression of
Slug in a keratinocyte cell line accelerates reepithelialization in an in vitro scratch
assay, and these cells have decreased desmosomes as evidenced by a
decrease in desmoplakin and desmoglein-3 expression (Savagner et al., 2005).
Similarly, expression of Slug was associated with a decrease in the desmosomal
components desmoplakin and desmoglein, but not E-cadherin in rat bladder
epithelial cells (Savagner et al., 1997).
Transcriptional repression is one mechanism for downregulation of
junctional proteins. Little is known about the role of this mechanism during
wound repair.
1.7.3.c Proteolytic cleavage
Proteolytic cleavage is a common mechanism for modulation of cell
membrane proteins function, as there are several proteases in the extracellular
environment including matrix metalloproteases (MMPs), a disintegrin and
metalloproteases (ADAMs) and plasmin and plasminogen activators. MMPs can
be activated by several growth factors that are present during wound healing,
including TGF-ß, PDGF, TNF-α, IL-1, FGF, EGF and KGF (Toriseva and Kahari,
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2009). During wound healing, several MMPs are expressed by keratinocytes at
the migrating wound edge, including, collagenase MMP-1, gelatinase MMP-9,
and stromelysins MMP-3 and MMP-10 (Madlener et al., 1998). Other MMPs that
are expressed during wound healing but not necessarily by migrating edge
keratinocytes include MMP-3, MMP-8, MMP-12, MT1-MMP, MMP-19, MMP-26
and MMP-28 (Toriseva and Kahari, 2009). ADAMs are transmembrane proteins
known to cleave ectodomains of membrane bound proteins and ADAM
substrates in wound repair are likely to be EGFR ligands (Sahin et al., 2004;
Sahin and Blobel, 2007). Plasminogen is the precursor to plasmin, which is
important for fibrin homeostasis as well as angiogenesis, two essential steps in
wound healing. Cleavage of plasminogen can occur by tissue plasminogen
activator (tPA), urokinase plasminogen activator (uPA), kallikrein and coagulation
factors XIa and XIIa. During wound healing, uPA is expressed by basal and
suprabasal keratinocytes (Romer et al., 1991), while its receptor, uPAR, is
expressed at the leading wound margin (Romer et al., 1994). Cleavage of
junctional components can be accomplished by various members of all three of
these proteolytic systems, and are described below.
Extracellular cleavage of E-cadherin is a well studied mechanism for
junctional disruption, and several proteases, including MMPs: MMP-3, MMP-7
(Davies et al., 2001; Noe et al., 2001), MMP-9 (Symowicz et al., 2007; Cowden
Dahl et al., 2008), MT1-MMP, ADAM10 (Maretzky et al., 2005) and ADAM15
(Najy et al., 2008), as well as plasmin (Ryniers et al., 2002), and kallikrein 7
(Johnson et al., 2007) calpain (Rios-Doria et al., 2003) and γ-secretase
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(Marambaud et al., 2002; Ferber et al., 2008) are reported to cleave E-cadherin.
The protease γ-secretase can cleave E-cadherin, and the cytoplasmic domain of
E-cadherin can then translocate to the nucleus and interact with DNA, possibly in
the regulation of apoptosis (Ferber et al., 2008).
Extracellular cleavage of desmosomal cadherins occurs in response to
pemphigus autoantibodies, apoptosis, and by MMPs and ADAMS. Pemphigus
vulgaris is an autoimmune disease in which patients develop antibodies against
desmoglein-3. The appearance of a 60 kD fragment of desmoglein-3 occurs in
vitro in keratinocytes treated with patient sera with pemphigus vulgaris (Cirillo et
al., 2008a). In apoptosis, both desmoglein-2 and desmoglein-3 undergo
cleavage events, by MMP-9 (Cirillo et al., 2007) and caspase-3 (Cirillo et al.,
2008b), respectively.
Other junctional proteins occasionally undergo proteolytic cleavage as well.
The tight junctions protein occludin is proteolytically cleaved by
metalloproteinases in endothelial cells after inhibition of tyrosine phosphatases
(Wachtel et al., 1999). No other tight junction or adherens junctional proteins
were affected, although desmosomal proteins were not investigated in this
system. The adherens junction protein ß-catenin is cleaved by the calcium
dependent protease calpain in both breast and prostate cancer cell lines upon
induced calcium influx (Rios-Doria et al., 2004). In keratinocytes, both ß-catenin
and plakoglobin are cleaved after UV exposure, by caspases-3 and -8 (Hung et
al., 2006), probably due to activation of an apoptotic pathway, as cleavage of
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these catenins by caspases is seen in endothelial cells undergoing apoptosis as
well (Herren et al., 1998).
Cleavage of all junctional proteins can be mediated by one or all of the
above mentioned proteolytic systems, although the main targets seem to be the
transmembrane cadherins. Many proteinases are found in wound fluid, and this
is a plausible mechanism of cadherin downregulation in wound healing.
Downregulation of cadherins by proteolytic cleavage is possible during the partial
epithelial to mesenchymal transition which occurs during wound healing and as
of yet has not been examined.
1.7.3.d Internalization and Trafficking
Internalization of proteins from the cell membrane occurs during routine
protein turnover, as well as in response to signal transduction pathways.
Transmembrane proteins can be internalized via micropinocytosis, clathrin
dependent or independent endocytosis, and caveolin dependent or independent
endocytosis (Figure 1.7.3). Once internalized, there are different possible
itineraries for the protein. Generally, internalized proteins enter a recycling
pathway, in which they are shuttled back to the cell membrane, or a degradation
pathway, in which they are destroyed either by the lysosome or proteosome.
Cadherins can undergo different types of internalization depending on the cell
type and stimulus presented.
The internalization of E-cadherin has been studied in several models and
clathrin-dependent (Le et al., 1999; Ivanov et al., 2004; Izumi et al., 2004; Bryant
et al., 2005; Palacios et al., 2005; Troyanovsky et al., 2006; Miyashita and
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Ozawa, 2007b), clathrin independent (Akhtar and Hotchin, 2001; Paterson et al.,
2003), and caveolae-dependent (Lu et al., 2003) internalization of E-cadherin
have been described, which vary according to the stimulus presented (Lu et al.,
2003; Bryant and Stow, 2004; D'Souza-Schorey, 2005). In basal conditions with
no stimulus, E-cadherin undergoes clathrin mediated endocytosis, then is
recycled back to the cell surface (Le et al., 1999). Once internalized with low
calcium, recycling of E-cadherin back to the plasma membrane after restoration
of normal calcium levels involved direct interaction with phosphatidylinositol
phosphate kinase and the AP1 complex (Ling et al., 2007). The scaffold protein
PALS1 is normally associated with tight junction formation, but also functions in
E-cadherin transport to the plasma membrane (Wang et al., 2007). The tight
junction protein occludin is also continuously recycled in a process dependent on
Rab13 (Morimoto et al., 2005). Junctional protein recycling is a possible
overarching mechanism for junctional regulation at basal conditions.
Various treatments of cells cause different results. Clathrin dependent
endocytosis (Figure 1.7.3, labeled in green) can occur in response to HGF
treatment (Palacios et al., 2002), low calcium conditions (Ivanov et al., 2004;
Ling et al., 2007) or the tyrosine kinase Src (Palacios et al., 2005). Researchers
using a cell free system also found clathrin dependent endocytosis of E-cadherin
that was inhibited by Rac activation (Izumi et al., 2004). E-cadherin cointernalizes
into early endosomes (Figure 1.7.3, labeled in green) with the tyrosine kinase
receptors c-Met and FGFR1 in response to HGF and FGF treatments,
respectively (Kamei et al., 1999; Bryant et al., 2005). The use of E-cadherin
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mutants revealed that E-cadherin that cannot bind p120 colocalizes with both
early and recycling endosomes (Miyashita and Ozawa, 2007b), and protein
kinase C (PKC) activation can also induce endocytosis and recycling of Ecadherin (Le et al., 2002). E-cadherin that cannot bind ß-catenin is targeted for
destruction via the lysosome (Miyashita and Ozawa, 2007a). Lysosomal
degradation also occurs after TGF-ß treatment, Raf-1 overexpression (Janda et
al., 2006), low calcium (Shen et al., 2008), and Src activation (Palacios et al.,
2005).
Clathrin independent endocytosis of E-cadherin is reported to occur after
various treatments as well. EGF treatment is reported to cause micropinocytosis
(Figure 1.7.3, labeled in red) of E-cadherin (Bryant et al., 2007) as well as
caveolar dependent internalization (Figure 1.7.3, labeled in yellow) (Lu et al.,
2003). Low calcium and Rac overexression also causes clathrin independent,
caveolar independent internalization of E-cadherin (Akhtar et al., 2000). Surface
labeled E-cadherin was found to be internalized by a clathrin independent,
dynamin dependent mechanism (Paterson et al., 2003).
The well studied E-cadherin can undergo various modes of internalization
after presentation of different stimuli (see Figure 1.7.3). Newly synthesized Ecadherin is transported to the plasma membrane from the Golgi via recycling
endosomes, and cycles through this recycling itinerary. Several stimuli, including
low calcium disruption of junctions, growth factors such as HGF, FGF and TGFß, as well as perturbance of molecules indicated in trafficking, such as Src or
ARF, can cause the clathrin dependent internalization and eventual degradation
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of E-cadherin in the lysosome. The same stimuli in other systems have been
found to cause non clathrin dependent internalization, including low calcium and
EGF causing caveolar internalization, whereas EGF has also been reported to
internalize E-cadherin by micropinocytosis and low calcium also causing clathrin
dependent internalization. It appears that the fate of E-cadherin is dependent on
both stimulus and cell type.
In contrast, very little is known about desmosomal cadherin regulation.
Early studies on desmosomal assembly focused on disruption of junctions by low
calcium conditions, then reassembly after restoration of calcium levels. The half
life of desmogleins 1-3 and desmoplakins 1-2 are decreased rapidly after
placement in low calcium (Penn et al., 1987) but continue to assemble what was
described as “half desmosomes” (Duden and Franke, 1988) that were
constitutively endocytosed in vesicles that associate with intermediate filaments.
Further studies found that desmosomes in low calcium were internalized in a
clathrin independent manner and are accumulated in cytoplasmic vesicles that
do not colocalize with lysosomal markers (Holm et al., 1993; Burdett and
Sullivan, 2002). The Burdett group found evidence of desmoglein-1 in
endosomes that did not label for early endosomes. These unknown endosomes
were able to fuse with late endosomes. After the switch from low calcium to
normal calcium levels the desmosomal cadherins desmoglein-1 and desmocollin2 were transported from the Golgi to the plasma membrane in two stages, first in
60 nM vesicles, then in 200 nM vesicles (Burdett and Sullivan, 2002).

72

Factors other than low calcium can cause the internalization of
desmosomal proteins. Desmoglein-1 is reported to be downregulated in
response to c-Met activation by HGF (Li et al., 2001), but it was not reported if it
was by a cleavage or internalization mechanism. Desmoglein-3, in response to
pemphigus antibody, an autoantibody produced in patients with the autoimmune
disease pemphigus vulgaris, was internalized and degraded in lysosomes in as
little as 1 hour, with complete loss of surface desmoglein-3 by 6 hours (Calkins et
al., 2006). However, when studying earlier timepoints (1 hour), the Kowalczyk
lab found this internalization to be a clathrin, dynamin, and caveolin independent
mechanism (Figure 1.7.4) most likely mediated by lipid rafts (Delva et al., 2008).
Desmosomal cadherins are less well studied, and although internalization
of desmosomes by low calcium appears to be a clathrin independent mechanism
that proceeds to late endosomes but not lysosomes, these studies were done
with electron microscopy techniques that recognize the electron dense
desmosome but not the individual members of the desmosome involved.
However, more recent studies focusing on desmoglein-3 internalization after
addition of autoantibodies against it also showed a clathrin independent
internalization that shuttled to endosomes (Figure 1.7.4), but in this case
lysosomal degradation did occur. Due to the small amount of information
available for desmosomal internalization, we focused on desmoglein-2, a very
abundant desmosomal cadherin, in response to EGF stimulation in the context of
wound healing.
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Figure 1.7.3
E-cadherin Internalization
Internalization of E-cadherin has been reported to occur by various mechanisms depending on
the stimulus. The majority of studies have shown clathrin dependent endocytosis, and either
recycling to the plasma membrane via recycling endosome or transfer to late endosomes and
lysosomal degradation. Other pathways such as micropinocytosis and caveolar dependent
endocytosis are less well studied but have been reported to occur. CCP = clathrin coated pit, RE
= recycling endosome, EE = early endosome, LE = late endosome, MVB = multivesicular body.
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Figure 1.7.4
Desmosomal Cadherin Internalization
Desmosomal cadherin internalization is less well studied than that of E-cadherin. The only
stimulus studied was the effect of pemphigus vulgaris autoantibody induced internalization of
desmoglein-3. In two separate studies by the Kowalczyk lab, desmoglein-3 was internalized in a
clathrin independent, dynamin independent pathway that is postulated to occur via lipid rafts.
After internalization, desmoglein-3 is transferred to the endosomal pathway where it eventually
undergoes lysosomal degradation.
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1.8 Hypothesis and rationale
Although it is clear that junctions are modulated during reepithelialization,
the underlying mechanisms are not well understood. One possible candidate for
being a cell-cell junctional modulator is EGFR. EGFR levels are upregulated at
wound margins in vivo (Wenczak et al., 1992) and due to the elevated EGFR
levels, the abundant EGFR ligands in the wound environment, and evidence that
EGFR activation can disrupt junctions (Cowden Dahl et al., 2008; Klessner et al.,
2008; Shen et al., 2008) the impact of the EGFR on two major adhesive junctions
is the focus of this dissertation. First, I examined the effects of elevated EGFR on
cadherin based cell-cell junctions in an in vitro model of reepithelialization
(Section 3.1). I hypothesized that elevated EGFR levels will disrupt cadherin
based cell-cell junctions after extended EGF treatment, causing a release of
transcriptional activators that will then cause upregulation of gene transcripts
involved in EMT-like events.
I then focused on the effects of EGFR activation on the individual
components of cell-cell junctions and their cytoskeletal counterparts in the
context of wound repair (Section 3.2). I hypothesized that EGFR activation will
cause disruption of both cell-cell junction components as well as disrupt their
cytoskeletal counterparts during wound healing. Any differences seen in
junctional components after EGFR activation could be due to either
downregulation of gene expression or post-transcriptional regulation. In order to
investigate what mechanisms are involved, I tested for differences in production
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of junctional components, including RNA and protein production in an EGFR
overexpressing cell line (Section 3.3). I compared the results of EGFR activation
to that of low calcium, a well studied mechanism of modulating junctions (Section
3.3). I hypothesized that EGFR will downregulate several junctional proteins and
that this will differ from what is seen with low calcium.
Due to the lack of information on cadherin regulation during wound
healing, I focused on the junctional cadherins E-cadherin and desmoglein-2, and
their fates after EGFR activation (Sections 3.4 and 3.5). I hypothesized that both
cadherins will undergo downregulation after EGFR activation.
Understanding the mechanisms of junctional modulations during wound
healing could reveal possible avenues of treatment for patients with non-healing,
chronic wounds. Identifying the junctional and cytoskeletal components
modulated during wound healing after EGFR activation will help us to identify the
mechanism by which EGF therapies are beneficial and could eventually help us
fine tune these treatments for increased efficacy.
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2

Methods
2.1 Cell Line and Reagents
Squamous cell carcinoma (SCC) 12F cells and SCC 13 cells were originally

derived from tumors of the facial epidermis and were generously provided by Dr.
William A. Toscano, Jr. (University of Minnesota, Minneapolis, MN) and Dr.
Kathleen Green (Northwestern University, Chicago, IL), respectively. SCC 12F
cells were maintained in 10cm2 plates in Dulbecco’s modified Eagle’s medium:
Ham’s F-12 nutrient mixture (DMEM:F-12) containing 5% (v/v) ironsupplemented defined calf serum (HyClone Laboratories, Inc., Logan UT), 2mM
L-glutamine and antibiotics (penicillin, 100U/ml, streptomycin, 50μg/ml). For all
experiments involving growth factor addition, SCC 12F cells were placed into
DMEM:F-12 containing 0.1% (w/v) bovine serum albumin (BSA) for 24 hours
prior to growth factor addition.
For low calcium experiments, cells were placed into DMEM:F12 depleted of
divalent cations using Chelex 100 Resin (BioRad, Hercules, CA) with addition of
50 μM CaCl2 and 1mM MgCl2 to the culture medium. SCC 13 cells stably
expressing control vector or EGFR were maintained as for SCC 12F except for
the addition of 300 μg/ml G418 to maintain selection (McCawley et al., 1997).
Murine epidermal growth factor (EGF) was obtained from Biomedical
Technologies Inc. (Stoughton, MA). GM6001X was purchased from Chemicon
(Temecula, CA). DMEM:F-12, BSA, Penicillin/Streptomycin and L-glutamine
were purchased from Sigma Chemical Co. (St. Louis, MO).
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2.2 Immunoblotting of protein and conditioned medium
Cells were lysed either with SDS collection buffer (10mM Tris pH 7.5, 1%
SDS, 5mM EDTA, 2mM EGTA, 1mM PMSF, 1 μg/ml leupeptin, 1 μg/ml pepstatin
A) to collect total protein, or by subcellular fractionation. For subcellular
fractionation, cells were lysed with 0.05% saponin collection buffer (10mM Tris
pH 7.5, 140mM NaCl, 0.05% saponin, 5mM EDTA, 2mM EGTA, 1mM PMSF, 1
μg/ml leupeptin, 1 μg/ml pepstatin A), then centrifuged at 14,000 rpm, and the
supernatant was called the saponin, or cytoplasmic, fraction. The pellet was then
fully resuspended in 1% triton collection buffer (10mM Tris pH 7.5, 140mM NaCl,
1% Triton X-100, 5mM EDTA, 2mM EGTA, 1mM PMSF, 1 μg/ml leupeptin, 1
μg/ml pepstatin A), then centrifuged, and the resulting supernatant was labeled
the triton soluble, or membrane fraction. Finally, the remaining pellet was fully
resuspended in 1% SDS collection buffer, and this was labeled the triton
insoluble, or cytoskeletal fraction. For experiments using nuclear extracts, the
protocol used is a modified Dignam protocol (Dignam et al., 1983). Cells were
collected in ice cold PBS, centrifuged, and the pellet was resuspended in buffer A
(1M Hepes-KOH, pH 7.9, 1M MgCl2, 1M KCl). After vortexing, the mixture was
centrifuged at 1700 rcf then supernatant was aspirated. The remaining pellet
(nuclear extract) was resuspended in buffer C (1M Hepes-KOH pH 7.9, 25%
glycerol (v/v), 1M KCl, 5M NaCl, 1M MgCl2, 0.5M EDTA).
Equal amounts of total protein were determined by bicinchoninic acid
(BCA) colormetric assay (Pierce, Rockford, IL). Equal quantities of protein were
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fractionated on 8% (w/v) SDS polyacrylamide gels and transferred onto
polyvinylidene fluoride (PVDF) membranes.
For experiments using conditioned medium, cells were treated, and
conditioned medium was collected from 6 well plates (1 mL total volume), then
concentrated using a centrifugal filter device (Millipore, Bedford, MA) with a
30,000 molecular weight cutoff. The retentate was collected and resolved on an
8% (w/v) SDS polyacrylamide gel, then transferred onto a PVDF membrane.
Immunoblotting was performed as described below. Membranes were blocked in
5% (w/v) non-fat dry milk in Tris buffered saline with 0.05% Tween-20 (TBST) for
1 hour at room temperature before the addition of primary antibody. Primary
antibodies were used at a 1:1000 dilution and included: ß-catenin (Santa Cruz,
Biotechnology, Santa Cruz, CA), plakoglobin (Santa Cruz Biotechnoloogy, Santa
Cruz, CA), Activated ß-catenin (Upstate, Temecula, CA), E-cadherin (clone NCH38, Dakocytomation, Carpinteria, CA), E-cadherin (Santa Cruz Biotechnology,
Santa Cruz, CA), desmoglein-2 (Invitrogen, Carlsbad, CA) and alpha-catenin
(Chemicon, Temecula, CA). Primary antibody was added, and the blot was
incubated at room temperature for 1 hour. The membranes were washed with
TBST 3 times, and secondary antibody horseradish peroxidase labeled goat antimouse from Promega (Madison, WI), at a dilution of 1:10,000 in 5% (w/v) milk,
was added for 1 hour at room temperature. The membranes were washed with
TBST 3 times and developed using the Supersignal chemiluminescent detection
system (Pierce, Rockford, IL). Visualization and densitometry of the blots was
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obtained with the Kodak Image Station 440 System (New England Nuclear,
Boston, MA).

2.3 Immunofluorescence
SCC 13 or 12F cells were seeded in a Lab Tek II chamber slide system
(Nalge Nunc International, Naperville, IL). Cells were transferred to serum-free
medium and then treated with 20 nM EGF for various times, or pretreated with
the broad spectrum MMP inhibitor GM6001X for 30 minutes prior to addition of
EGF. To probe for junctional proteins, cells were fixed with cold dry methanol for
2 minutes or alternatively with freshly prepared paraformaldehyde (3.7%) for 10
minutes. To look for cytoplasmic staining, paraformaldehyde slides were
permeabilized with 0.01% (w.v) Triton X-100 (Sigma, St. Louis, MO) for an
additional 5 minutes. The slides were then blocked in 3% (w/v) BSA in complete
PBS (phosphate buffered saline containing 0.8 mM magnesium chloride and 0.18
mM calcium chloride) at 37º C in a humidified chamber. For lysosomal detection,
Lysotracker (Invitrogen, Carlsbad, CA) was added at a 1:250 dilution to live cells
2 hours before fixation.
Primary antibodies were used at a 1:100 dilution and included: ß-catenin
(Chemicon, Temecula, CA), plakoglobin, caveolin-1, pancytokeratin (Santa Cruz,
Santa Cruz, CA), E-cadherin (HECD-1 clone), desmoglein-1, desmoglein-2
(Invitrogen, Carlsbad CA), EEA1 (Affinity Bioreagents, Golden, CO), epidermal
growth factor receptor (EGFR) (Upstate, Chicago, Il.), rab11 (clone p71, NM275,
rabbit polyclonal Ab) and rab7 (clone , both kindly provided by Dr. Angela
Wandinger-Ness, University of New Mexico). Primary antibody was allowed to
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incubate for 1 hour at 37ºC in a humidified chamber. Slides were washed 3
times in complete PBS, then a fluorophore conjugated secondary antibody
(Invitrogen, Carlsbad, CA) was added at a 1:300 dilution, and was further
incubated for 1 hour at 37ºC in a humidified chamber. Actin staining was
obtained by incubating with TRITC-labeled Phalloidin (0.5 μg/ml in PBS, Sigma,
St. Louis, MO) for 30 minutes at room temperature. Slides were washed 3 times
in complete PBS then mounted with a coverslip using Vectashield mounting
medium (Vector Labs, Burlingame, CA). Images were obtained with an inverted
microscope (Olympus IX70, Melville NY) and MagnaFire software 2.1 (Optronics,
Goleta, CA) or with a Zeiss confocal Microscope (Zeiss, Thornwood, NY).

2.4 Wound Healing Assay
For evaluation of in vitro reepithelialization, confluent cell monolayers were
deprived of serum and growth factors for 24 hours, and a cell-free area was
introduced by scraping the monolayer with a standard dimension blue pipette tip
(USA Scientific, Ocala, FL) followed by extensive washing to remove cellular
debris. In vitro reepithelialization was monitored by repopulation of the cleared
area (wound width typically between 200–300 mm) with cells over time either in
the presence or absence of 5 μM of the EGFR inhibitor AG1478 (Alexis/Axxora
Inc., San Diego, CA). Quantification of wound area was obtained by measuring
area before and after reepithelialization using digital pictures and ImagePro
(Media Cybernetics, Inc., Bethesda MA) software.

82

2.5 Polymerase Chain Reaction (PCR)
RNA was isolated using 0.5 ml Trizol (Invitrogen Life Technologies, Carlsbad,
CA), following the manufacturer’s instructions. cDNA was synthesized from total
RNA. All PCR reagents were purchased from Promega (Madison, WI). Primers
were ordered from Sigma-Genosys (The Woodlands, TX) and included the
following: E-cadherin (Forward, GGGTGACTACAAAATCAATC, Reverse,
GGGGGCAGTAAGGGCTCTTT), desmoglein-2 (Forward,
CACTATGCCACCAACCACTG, Reverse, TTAGGCATGGCCAGAGTAGG), and
18s rRNA (Forward, AAACGGCTACCACATCCAAG, Reverse,
CCTCCAATGGATCCTCGTTA), Slug (Forward,
CCCTGAAGATGCATATTCGGAC, Reverse, CTTCTCCCCCGTGTGAGTTCTA),
tenascin-C (Forward, GGCATTGAGCTGACCTACGG, Reverse,
CTTTGGCTGGGTTGCTTGAC). E-cadherin amplification was performed with
an initial denaturation step at 94ºC for 4 minutes, followed by 38 cycles with a
denaturing step at 94º for 30 seconds, an annealing step of 55ºC for 30 seconds
and an extension step of 72ºC for 30 seconds, and a final extension step of 72 ºC
for 4 minutes. Desmoglein-2 amplification was performed as above, with the
annealing step of 64ºC for 30 seconds, with a total of 30 cycles. 18s rRNA
amplification was performed with an initial denaturation step at 94ºC for 4
minutes, followed by 20 cycles with a denaturing step at 94º for 30 seconds, an
annealing step of 55ºC for 30 seconds and an extension step of 72ºC for 30
seconds, and a final extension step of 72 ºC for 4 minutes. Slug amplification
was performed with an initial denaturation step at 94ºC for 3 minutes, followed by
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36 cycles with a denaturing step at 94º for 30 seconds, an annealing step at 60ºC
for 30 seconds and an extension step at 72ºC for 60 seconds, and a final
extension step of 72 ºC for 7 minutes. Tenascin-C amplification was performed
with an initial denaturation step at 94ºC for 4 minutes, followed by 35 cycles with
a denaturing step at 94º for 30 seconds, an annealing step at 67ºC for 30
seconds and an extension step at 72ºC for 30 seconds, and a final extension
step of 72 ºC for 7 minutes.
GoTaq Flexi products (Promega, Madison, WI) were used for PCR. The resulting
PCR products were loaded onto a 3% agarose gel (EMD Chemicals, San Diego,
CA). SYBR Safe DNA gel stain (Invitrogen, Carlsbad, CA) was added for
staining purposes, and the gel was imaged on a Kodak Image Station 440
System (New England Nuclear, Boston, MA).

2.6 Statistical Analysis
Due to the small samples sizes in my studies (n=3), I cannot test for normal
distribution, so a nonparametric test is needed to analyze my results (Daniel,
1987). Due to the small sample size, I also cannot assume equal variance
(Motulsky, 1999). Results from different treatment groups in immunoblotting
experiments were compared by using the nonparametric Welsh’s t test, and the
value for statistical significance was considered at p<0.05.
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3

Results
3.1 Elevated EGFR required for junctional disruption
Since the EGFR is elevated at the edge of wound margins in vivo, it is

possible that increased receptor expression alters keratinocyte function. To test
this hypothesis, the first goal was to identify potential differences in junctional
disruption due to contributions of the EGF receptor. I used the squamous
carcinoma cell line SCC 13, a cell line from a tumor of the facial epidermis that
normally expresses low levels of the EGFR (~40,000 receptors/cell), as well as
SCC 13 cells that were transfected to moderately overexpress (about 5 fold,
~200,000 receptors/cell) EGFR (Hudson and McCawley, 1998) . EGF dependent
morphological differences are apparent between the parental cells and the EGFR
overexpressing cells. SCC13 cells transfected with vector alone maintain an
epithelial morphology, exemplified by their round shape, cobblestone
appearance, and tight colony formation following exposure to EGF. In contrast,
EGFR overexpressing cells have an elongated, spindle-like morphology, typical
of an EMT-like transition to a fibroblastic-like phenotype (Figure 3.1.1). The
transition occurs approximately 8 hours post EGF treatment, and extends
throughout 24-48 hours of treatment in EGFR overexpressing cells. In contrast,
even after 48 hours of continuous EGF stimulus, vector control cells maintain
their epithelial morphology and remain in tight colonies.
In order to determine if the lack of response by the SCC 13 vector control
cells was due to the concentration of EGF, the effects of different concentrations
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was investigated. Cells were treated either with vehicle alone (control), 10 nM
EGF, or 100 nM EGF for 24 hours (Figure 3.1.2). At 24 hours, EGFR cells were
elongated and spindle shaped in response to EGF treatment. Vector control
cells, however, maintained their tight colonies at both the 10 nM and 100 nM
EGF concentrations. This indicates that vector control cells, with low levels of
the EGFR are resistant to ligand dependent scattering regardless of both time
(Figure 3.1.1) and EGF concentration (Figure 3.1.2). However, under low
calcium conditions in which junctions are already disassembled, both vector
control and EGFR cells migrate in response to EGF (McCawley et al., 1997).
This indicates that colony disruption under conditions of intact junction (normal
calcium levels) in the SCC 13 cell line is dependent on elevated EGFR levels and
that the predominant effect of elevated EGFR is on the modulation of junctions
rather than cell migration.
Although the cell scattering indicates a loss of cell-cell junctions,
confirmation requires immunofluorescent staining for individual junctional
components. ß-catenin was used as a marker for adherens junctions, while
desmoglein-2 was used as a marker of desmosomes. After treating both the
vector control cells and the EGFR overexpressing cells for various timepoints up
to 24 hours with EGF, differences between the two cells lines became evident.
Vector control cells maintained both adherens junctions and desmosomes at the
cell-cell border, indicative of intact junctions (See figures 3.1.3 and 3.1.4, left
panels). However, cells overexpressing the EGFR had a decrease in cell border
staining of both the adherens junction protein ß-catenin and the desmosomal
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protein desmoglein-2 around 6 hours post EGF treatment (Figures 3.1.3 and
3.1.4, right panels). By 24 hours, most of the desmoglein-2 and nearly all of the
ß-catenin was no longer present at cell-cell junctions (Figures 3.1.3 and 3.1.4,
white arrows), indicating that elevated EGFR is necessary for junctional
dissolution, as suggested by the colony disruption findings. The characteristic
change in morphology was also seen after 24 hours post EGF treatment
(comparte 3.1.1 with 3.3.4). Differences in staining intensities were observed
between the vector control cells and the EGFR overexpressing cells for both ßcatenin and desmoglein-2. This may be an artifact of the convential microscopy
technique, because no differences in intensities were seen with confocal
microscopy for ß-catenin staining (Figure 3.1.7).
In order to evaluate protein levels for junctional components after EGF
treatment, cells were collected in SDS protein lysis buffer and processed for
immunoblotting to detect the junctional cadherins E-cadherin and desmoglein-1.
While it appears that cadherin levels decrease in EGFR overexpressing cells
after EGF treatment, there were no statistically significant differences for either
cadherin 24 hours after EGF exposure (Desmoglein-1, vector cells control vs.
EGF (p=0.2987); EGFR cells, control vs. EGF (p=0.6444) in a total of 3
independent experiments) (Figure 3.1.5). Similar results were observed for Ecadherin. No statistically significant difference was detected in vector cells control
vs. EGF (p=0.1772) and the EGFR cells (p=0.2987) in a total of 3 independent
experiments (Figure 3.1.5). The trend toward cadherin decrease after 24 hours
of EGF treatment, even though not statistically significant, combined with the
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immunofluorescence data revealing loss of protein from the cell-cell junctions
(Figure 3.1.3 and 3.1.4) indicates a possible role for elevated EGFR levels and
junctional breakdown specifically via cadherin modulation.
Because the EGFR has been reported to modulate ß-catenin, levels of
this protein were evaluated following EGF treatment in vector control and EGFR
overexpressing cells. No EGF dependent changes in ß-catenin were detected
between the 0h and 24 hour timepoints in both the vector alone cells (p=0.99),
and in the EGFR overexpressing cells (p=0.7955) (Figure 3.1.6). This finding
suggests that EGF-stimulated junctional breakdown is targeted at the cadherin
portion of the junction.
ß-catenin not only functions as a part of the junctional complex, but can
also act as a transcriptional regulator when translocated to the nucleus. Two
classes of ß-catenin target genes have been identified. The first, or classical ßcatenin targets, are genes important in cell survival, proliferation and apoptosis
(Moon et al., 2002). The second, or non-classical ß-catenin target genes, are
those important in EMT, such as Slug, tenascin-C, survivin, and MMP14
(Brabletz et al., 2005). To test whether there may be differences in ß-catenin
signaling, cells were treated with EGF, and nuclear localization of ß-catenin was
examined. Vector control cells showed intense cytoplasmic staining for ßcatenin (Figure 3.1.6) with 48 hours EGF treatment, although not all the nuclei of
cells stain positive for ß-catenin. However, EGFR overexpressing cells have
both cytoplasmic and nuclear staining of ß-catenin. This indicates that
overexpression of the EGFR causes a redirection of at least a portion of the total
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ß-catenin pool to the nucleus. Similar results were observed following 5.5 hours
of EGF treatment, as EGFR overexpressing cells had a portion of the total
population staining positive for nuclear ß-catenin (Figure 3.1.7, white arrows).
This asynchronous nuclear localization of ß-catenin is apparent at several
timepoints in EGFR overexpressing cells after EGF addition, and suggests that
ß-catenin nuclear localization could be important throughout reepithelialization.
Another way to further investigate the impact of elevated EGFR levels on
keratinocyte function is to use a cell line that has endogenously elevated EGFR
levels. The SCC 12F cell line is originally of head and neck origin, and has
endogenous overexpression of EGFR levels, similar to the levels seen in the
transfected SCC 13 EGFR cell line (McCawley et al., 1997). The response of
SCC 12F cells treated with EGF for various timepoints was comparable to that of
the EGFR overexpressing SCC 13 cells. While it appears that there is a
decrease in ß-catenin protein in SCC 12F cells (Figure 3.1.8), no statistically
significant changes occurred between control and 24 or 48 hours post treatment
(24h p=0.5117, 48h p=0.5150). ß-catenin mRNA levels were investigated to
determine if elevated EGFR levels might be causing transcriptional repression of
ß-catenin (Figure 3.1.9). No changes in ß-catenin transcript levels were seen,
indicating that the junctional protein is not being modulated by this mechanism.
Nuclear localization of ß-catenin in SCC 12F cells was apparent around 4
hours post treatment (Figure 3.1.10, white arrow), but is transient, as no nuclear
localization of ß-catenin was evident at 6 hours post treatment. This timecourse
is in agreement with the SCC 13 EGFR cells short time course. In order to
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confirm the presence of ß-catenin in the nucleus, nuclear extracts were collected
after an EGF timecourse from 2-48 hours. Using an antibody that recognized the
activated form of ß-catenin, which is dephosphorylated on Ser-37 or Thr-41, an
increase in ß-catenin is apparent after 2 hours EGF treatment and is persistent at
24 and 48 hours post EGF treatment (Figure 3.1.11).
However, this nuclear localization of transcription factors is not global, as
the ß-catenin family member plakoglobin did not undergo nuclear localization at
the same timepoints (Figure 3.1.12). Although plakoglobin mirrored ß-catenin in
regards to protein (Figure 3.1.8) and transcript levels (Figure 3.1.9) after EGF
treatments, at 5.5 hours post EGF treatment, both vector control cells and the
EGFR overexpressors maintained plakoglobin at cell-cell junctions, indicating
that EGFR overexpression preferentially relocalizes ß-catenin to the nucleus, but
not its family member plakoglobin.
The next step was to investigate the possibility of altered gene expression
as a function of ß-catenin nuclear localization due to increased EGFR levels.
Non-classical downstream targets of ß-catenin include the transcriptional factor
Slug and the extracellular protein tenascin-C, both of which have been
associated in cells with an EMT-like phenotype in development and cancer. In
wound healing, tenascin-C is upregulated early, and has been shown to be
produced by keratinocytes (Latijnhouwers et al., 1997). Slug, as mentioned
earlier, is required for EGFR dependent reepithelialization (Savagner et al.,
2005). In order to look at transcriptional upregulation of these ß-catenin target
genes, RT-PCR of Slug and tenascin-C was performed (Figure 3.1.13) from RNA
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collected after different timepoints of EGF treatment. An induction of the Slug
transcript is visible after 1 hour of EGF treatment, and is persistent up to 4 hours
post treatment. Tenascin-C is upregulated 24-48 hours post EGF treatment.
This indicates that two known ß-catenin transcriptional targets are upregulated
after EGFR activation in a SCC cell line that moderately overexpresses the
EGFR.
Overall, these data provide evidence that increased availability of ligand
and transient increase of EGFR that is present at the wound margin leads to
keratinocyte modification of its cell-cell junctions. An increase in EGFR levels is
necessary for junctional disruption in keratinocytes and this disruption likely leads
to ß-catenin dependent transcription events that may regulate classical targets,
such as cell proliferation genes cyclin-D, as well as non-classical targets
important in EMT events, including the transcription factor Slug and the
extracellular matrix protein tenascin-C. Regulation of ß-catenin target genes
could be a contributing factor to cell migratory behavior during reepithelialization.
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Figure 3.1.1
Elevated EGFR levels required for cell scattering.
EGF timecourse comparison of SCC13 cells transfected with vector alone, or with a vector
containing EGFR. With no treatment both sets of cells display an epithelial morphology that is
retained up to 4 hours post EGF treatment. However, from 8-48 hours post EGF treatment,
EGFR overexpressing cells scatter, typical of a loss of cell-cell junctions in an EMT-like event.
Vector control cells with low levels of EGFR maintain their epithelial shape and do not scatter in
response to EGF.
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Figure 3.1.2

SCC 13 Vector control cells do not migrate in response to increased levels
of EGF
SCC 13 Vector control cells and EGFR overexpressing cells were serum starved overnight, then
treated with either 10 nM EGF or 100 nM EGF for 24 hours. EGFR overexpressing cells scatter
at both concentrations. Vector control cells remain in colonies regardless of the concentration of
EGF present.
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Figure 3.1.3
Elevated EGFR necessary for adherens junction disruption
SCC13 cells transfected with vector alone or with EGFR were treated for increasing times with 20
nM EGF. Cells were then fixed and immunofluorescently labeled for the adherens junction
protein ß-catenin. Adherens junction disruption is visible by the loss of ß-catenin staining (white
arrows) in the EGFR overexpressing cells, while vector control cells maintain junctions for at least
24 hours post EGF treatment.
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Figure 3.1.4
Elevated EGFR is required for desmosomal disruption
SCC13 cells transfected with vector alone or with EGFR were treated for increasing times with 20
nM EGF. Cells were then fixed and immunofluorescently labeled for the desmosomal protein
desmoglein-2. Desmosomal junction disruption is visible by the loss of desmoglein staining (white
arrows) in the EGFR overexpressing cells, while vector control cells maintain junctions for at least
24 hours post EGF treatment. The shape change in morphology, similar to what is seen in
Figures 3.1.1. and 3.1.2 is also visible in the EGFR overexpressing cells in this experiment.
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Figure 3.1.5
Elevated EGFR does not significantly decrease total cadherin protein levels
SCC13 cells transfected with either vector alone or with EGFR were serum starved overnight.
Total protein was collected after no treatment or treatment with 20 nM EGF for 24 hours. Both Ecadherin and desmoglein-1 appear to decrease after EGF treatment in EGFR overexpressing
cells, but not to a statistically significant degree as measured by densitometry.
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Localization of β-catenin differs between control and EGFR overexpressing
cells without alterations in total protein levels
A. SCC13 cells transfected with either vector alone or with EGFR were serum starved overnight.
Total protein was collected after no treatment or treatment with 20 nM EGF for 24 hours. There is
no change in ß-catenin protein levels between the untreated and 24 hour treated cells for either
the vector alone cells nor the EGFR overexpressing cells. B. SCC13 vector cell line and EGFR
cell line were serum starved for 24 hours, then treated with either vehicle (0h) or EGF for 48
hours. After cell fixation, cells were permeabilized and stained for ß-catenin. Cytoplasmic ßcatenin is visible in both vector alone and EGFR cells. However, 48 hours post EGF treatment,
nuclear localization of ß-catenin is visible only in the EGFR transfected cells.
Figure 3.1.6
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Figure 3.1.7

Nuclear localization of ß-catenin after EGF stimulation requires elevated
EGFR levels
SCC13 cells transfected with either vector alone or with EGFR were serum stared overnight then
treated with vehicle (0h) or with 20 nM EGF for 5.5 hours. After fixation and permeabilization,
cells were stained for ß-catenin. While vector control cells show no change in border staining for
ß-catenin, populations within the EGFR cells show nuclear staining after 5.5 hours of EGF
treatment.

98

Figure 3.1.8
Catenins show decreasing trend after EGF treatment in SCC 12F cell line.
Cells were grown to subconfluence, placed in serum free medium overnight, and then treated
with EGF for various timepoints. Although both ß-catenin and plakoglobin decrease upon
extended time with EGFR activation, the observed decrease was not statistically significant.
Results are representative of a minimum of three separate experiments. Bar graphs represent
the densitometric quantification of each lane normalized to no treatment control.
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Figure 3.1.9

Neither β-catenin nor plakoglobin are transcriptionally regulated following
EGF treatment
SCC 12F were serum starved and treated with 20 nM EGF for various timepoints. Total RNA
was collected and RT-PCR performed. No change in ß-catenin or plakoglobin transcription
occurs between 2 to 48 hours post EGF treatment. GAPDH represents loading control.
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Figure 3.1.10

SCC 12F cells display transient nuclear localization of ß-catenin following
short term EGF exposure.
SCC 12F cells were serum starved overnight and treated for 2-6 hours with 20 nM EGF. Cells
were then fixed, permeabilized, and stained for ß-catenin. A transient nuclear localization of ßcatenin is apparent at 4 hours post EGF treatment (white arrow), similar to the timeframe for the
SCC 13 EGFR cells (see Figure 3.1.7).
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Figure 3.1.11

ß-catenin protein is increased in nuclear extracts following extended EGF
treatment.
SCC 12F cells were serum starved overnight and treated with 20 nM EGF for the indicated times.
Cells were scraped and the nuclear extract was isolated. Using an antibody specific for active ßcatenin, we see an increase in the total amounts of ß-catenin found in the nucleus upon extended
EGF treatment.
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Figure 3.1.12

Neither vector nor EGFR overexpressing cells have nuclear plakoglobin
following short term EGF treatment
SCC 13 cells transfected with either vector alone or with EGFR were serum starved overnight
and then treated with vehicle (0h) or with 20 nM EGF for 5.5 hours. After fixation and
permeabilization, cells were stained for plakoglobin. Neither vector control cells nor EGFR cells
show any change in border staining for plakoglobin.
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Figure 3.1.13

Non-classical ß-catenin targets are upregulated after EGF treatment in
SCC 12F cell line
SCC 12F cells were serum starved and treated with 20nM EGF for the indicated times. Total
RNA was isolated and RT-PCR against Slug and tenascin-C transcripts reveals a modest
upregulation in Slug transcript by 1 hour post EGF treatment that increases at 2 hours and
remains persistent up to 4 hours post treatment. Tenascin-C transcript is upregulated after 2
hours at 24 hours post EGF treatment and persists up to 48 hours.
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3.2

Effects of elevated EGFR at wound margins on
junctional and cytoskeletal components
EGF receptor activation has been reported to stimulate wound repair in

vivo (Nanney et al., 2000; Repertinger et al., 2004) and disrupt junctional
complexes in vitro (Bhora et al., 1995; Hudson and McCawley, 1998). We
conducted in vitro wound closure assays using SCC 12F cells, a welldifferentiated squamous cell carcinoma line (Hudson et al., 1986) to investigate
the status of desmosomal and adherens junctions at an in vitro wound border
upon EGFR inhibition (Figure 3.2.1).

The goal of this experiment was to

investigate the contributions of EGFR activation under basal (serum free
conditions), serum stimulated conditions, as well as EGF stimulated conditions.
Contributions of the EGFR were singled out by using AG1478, an inhibitor that
affects the catalytic domain of the receptor. Wound closure in serum free
conditions (addition of BSA) occurs to a small degree (around 15%) even in the
absence of exogenous EGF, however, the increase in wound closure is greatly
increased with the addition of EGF (Figure 3.2.1). Migration into the wound area
was substantially inhibited by inclusion of EGFR tyrosine kinase inhibitor AG1478
in the culture medium, indicating that activated EGFR is involved in the response
(Figure 3.2.1). Inhibition of the EGFR also decreases migration in serum
containing conditions, indicating the contribution of the EGFR even in the
presence of other serum proteins. Again, inhibition of the EGFR with AG1378
attenuates the migration of cells regardless of the presence of EGF. An
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interesting finding in this set of wound closure assays was the decline of the
basal, unstimulated response of these cells upon EGFR inhibition both in the
serum free and serum containing experiments. Autocrine production of EGF in
keratinocytes has been reported (Pittelkow et al., 1993) and could be responsible
for both the unstimulated response and the corresponding decrease seen with
EGFR inhibition in the serum free conditions. The decrease in migration in the
presence of serum upon EGFR inhibition indicates the necessity of this pathway,
even when migration is being stimulated by ligands other than EGF.
EGFR activity upon EGF stimulation was responsible for cell scattering
and eventual junctional disruption in cells with elevated EGFR (Section 3.1). In
addition, junctional disruption was detected at wound margins as evidenced by
the loss of catenin border staining for both ß-catenin and plakoglobin (Figure
3.2.2, arrows). Positive catenin staining at the wound edge in serum free,
unstimulated conditions with EGFR inhibition suggests that junctional integrity
was retained once the EGFR was no longer active (Figure 3.2.2, arrowheads). It
is likely that both desmosomal and adherens junctional components are sensitive
to EGFR activity. As might be expected, cadherin staining was also altered at the
wound margin (Figure 3.2.3). Whereas cells with no treatment and presumably
elevated EGFR activity had disrupted cadherin staining (Figure 3.2.3, white
arrows), cells under conditions of EGFR inhibition (+AG1478) had stronger cell
staining at cell borders at the wound margin (Figure 3.2.3, white arrowheads).
In order to confirm that the loss of junctional proteins from the cell surface
results in disruption of a functional junction, we used confocal microscopy to look
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at the scaffolding proteins at the junction in relationship to their associated
cytoskeletal attachments in the context of wound healing. The actin cytoskeleton
is indicated by the marker phalloidin (Figure 3.2.4), and the intermediate
filaments are indicated by staining for cytokeratin (Figure 3.2.5). Both sets of
cytoskeletal markers were shown to lose their organization at the wound edge 1
day post wounding (right panels). Upon EGFR inhibition, this disorganization
was less apparent, as the cells appeared to maintain their cytoskeletal structure
right up to the wound margin. Cells at the confluent interior (left panels) had no
such defects in structure after wounding. Actin stress fibers and the keratin
intermediate filament network were evident in the confluent monolayer and
showed a great deal of organization as evidenced by the filamentous extentions
across the entirety of the cell up to the cell borders, although it did appear that
with EGFR inhibition, less overall stress fibers were evident (Figure 3.2.4, bottom
right panel), although junctional integrity was maintained.. These results indicate
that cytoskeletal disruption, and in effect, junctional disruption, are localized to
the wound margin, are dependent on EGFR activity, and do not consist of a
global signaling throughout the monolayer.
Reepithelialization represents a partial and reversible EMT in vivo, so the
timeline of junctional disruption in our system was further investigated. Cells
were allowed to grow out into the wounded area from 1 to 3 days. After 3 days,
junctional proteins plakophilin (Figure 3.2.6) and ß-catenin (Figure 3.2.7) were
apparent at the borders of cells at the wound margins. Both cytokeratin staining
(3.2.6) and the actin cytoskeleton (Figure 3.2.7) have restored their organization
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in cells at the wound margin, which is now identical to the staining found in cells
in the confluent interior. This indicates that the modulation of the cell-cell
junctions and their corresponding cytoskeletal components by the EGFR is a
transient and reversible phenomenon.
These data collectively demonstrate EGFR dependent junctional
disruption, cytoskeletal reorganization, and cell migration, even in the absence of
exogenous EGF. These phenomena are limited to the wound margin, as cells
distant to the wound edge are unaffected. Indeed, a recent study found that
patients with chronic, non-healing wounds have a marked reduction of EGFR
levels in the ulcerated epidermis as compared to adjacent, nonulcerated skin
(Brem et al., 2007), indicating the clinical relevance to our in vitro studies.
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Figure 3.2.1

SCC12F cells in vitro reepithelialization highlights necessity of EGFR for
wound closure
SCC 12F cells were grown to confluence, placed in serum free medium overnight, and then a
wound was introduced with a pipette tip. Cells were washed 3 times with PBS and then returned
to serum free medium +/- 5 uM of the selective EGFR inhibitor AG1478. The area of wound
closure was measured using ImagePro software and compared with the inclusion or absence of
serum in the medium concurrently in the presence of EGF or AG1478. Upon EGFR inhibition,
migration into the wounded area is impaired. This inhibition occurs in both serum free medium
and in serum containing medium, indicating the importance of EGFR activation in cell migration.
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Figure 3.2.2
Catenin Immunofluorscence at wound edge shows junctional protection
After wounding, SCC 12F cells were washed 3 times with PBS, then placed back in serum free
medium +/- 5 uM of the selective EGFR inhibitor AG1478. After 24 hours, cells were fixed and
immunostained for either plakoglogin or ß-catenin. Note the loss of border staining is limited to
the wound edge (arrows). Upon EGFR inhibition, junctional proteins are apparent at the wound
edge (arrowheads).
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Figure 3.2.3

Cadherin immunofluorescence at wound margin reveals junctional
protection with the EGFR inhibitor AG1478
After wounding, SCC 12F cells were washed 3 times with PBS, then placed back in serum free
medium +/- 5 uM of the selective EGFR inhibitor AG1478. After 24 hours, cells were fixed and
immunostained for either E-cadherin or desmoglein-2. Note the loss of border staining is limited
to the wound edge (arrows). Upon EGFR inhibition, junctional proteins are apparent at the wound
edge (arrowheads).
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Figure 3.2.4
Actin cytoskeleton maintained at wound margin with inhibition of EGFR
activity
SCC 12F cells were grown to a confluent monolayer, and then a mechanical wound was
introduced. The cells were then grown in low serum media with or without the addition of
AG1478 for 24 hours then fixed and stained for cytoskeletal marker F-actin. Disregulation of the
actin cytoskeleton is visible in the upper right hand panel, in which the EGFR is not inhibited, and
disorganization is restricted to the wound edge area, as the interior of the wound (left hand
panels) are undisturbed.
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Figure 3.2.5

Cytokeratin organization maintained at wound edge with inhibition of EGFR
activity
SCC12F cells were grown to a confluent monolayer, and then a mechanical wound was
introduced. The cells were then grown in low serum media with or without the addition of
AG1478 and stained for interfilament marker cytokeratin proteins. Similar to the results for the
actin cytoskeleton, intermediate filaments as the wound edge are disturbed when the EGFR is not
inhibited. This disruption is localized to the wound edge, as the confluent interior (left panels)
shows no defects in organization.
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Figure 3.2.6

Disruption of cytokeratin cytoskeleton at the wound margin is transient,
and restored 3 days post wounding.
SCC 12F cells were grown to a confluent monolayer, and then a mechanical wound was
introduced. The cells were then grown in low serum media with or without the addition of
AG1478 for 24 hours then fixed and stained for the desmosomal junctional protein plakophilin
(green staining) and the intermediate filament protein cytokeratin (red staining). 3 days post
wounding, junctions are restored, as evidenced by plakophilin-2 (Pkp2) staining at the wound
margin and reorganization of the actin cytoskeleton.
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Figure 3.2.7

Disruption of actin cytoskeleton at the wound edge is transient, restored
after 3 days post wound
SCC 12F cells were grown to a confluent monolayer, and then a mechanical wound was
introduced. The cells were then grown in low serum media with or without the addition of
AG1478 for 24 hours then fixed and stained for the adherens junction protein ß-catenin (green
staining) and the cytoskeletal marker F-actin (Red staining). 3 days post wounding, junctions are
restored, as evidenced by ß-catenin staining at the wound margin and reorganization of the actin
cytoskeleton.
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3.3

Differences in EGF stimulated changes in Adherens
Junctions versus Desmosomes
EGFR has been reported to modulate intracellular junctional proteins,

namely the catenins, by various mechanisms, such as phosphorylation, leading
to down-regulation and protein degradation (See Section 1.7.3, Table 2). As the
catenins are very well studied in response to EGFR activation, we decided to
focus on the cadherin responses to EGFR activation by EGF. Cadherins are
also regulated in different systems, with varied routes of regulation possible
(Figure 1.7.2). Whole cell extracts were collected and examined to determine if
differences existed between the SCC 12F cells and the earlier mentioned SCC
13 cells, which showed no statistically significant differences in the cadherin
levels after 24 hours of EGF treatment (Figure 3.1.5). Although SCC 12F cells
have similar amounts of EGFR as the SCC 13 EGFR cell line (McCawley et al.,
1997), we see a statistically significant decrease in desmoglein-2 cadherin levels
after 24 hours EGF treatment as compared to the SCC 13 EGFR cell line (Figure
3.3.1 A vs. Figure 3.1.5). No change was seen in desmoglein-1 cadherin after 24
hours in the SCC 13 cell line, which may be due to differences in the cell line or
in the kinetics of regulation between the two desmoglein isoforms. E-cadherin
levels decreased to a statistically significant amount after 48 hours of EGF
treatment (Figure 3.3.1 A). SCC 13 E-cadherin protein levels appeared to be
decreasing at 24 hours, but it was not statistically significant (p<0.05). Total
cadherin protein levels in the SCC 12F cells decreased after EGF treatment, but
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it was not clear if certain pools were preferentially targeted. Using sequential
detergent extraction, I was able to compare protein levels of membraneassociated (triton soluble) versus junction-bound (triton insoluble) cadherins. I
found that extended exposure to EGF redistributed both the desmosomal
cadherin desmoglein-2 and adherens junction protein E-cadherin from the cell
membrane (Figure 3.3.1 B) as well as from preformed junctions (Figure 3.3.1 C).
Interestingly, not all junctional components were affected, as there was no
decrease in total protein of the adherens junctional linker protein α-catenin
(Figure 3.3.1).
Although both cadherins were being redistributed in response to EGF, I
saw a difference in the time dependent loss of individual cadherin proteins in
response to EGF in the membrane-associated and junction-associated protein
pools. The triton soluble, membrane-associated fraction showed a decrease in
desmoglein-2 protein as early as 6 hours, whereas a statistically significant
decrease in E-cadherin levels does not occur until 24 hours (Figure 3.3.1 B,
asterisks). Similar to the triton soluble fraction, the triton insoluble fraction, which
contains intact junctions, did not show statistically significant decrease in Ecadherin until 24 hours post EGF treatment. Desmoglein-2, however, had a
statistically significant decrease as early as 2 hours post EGF treatment (Figure
3.3.1 C, asterisks). In all cases, we saw that cadherins were lost from cell
membrane pools in response to EGF and that desmoglein-2 was preferentially
lost first. This suggests that desmosomes are modulated by EGF exposure
through different mechanisms than adherens junctions.
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Since transcriptional repression of E-cadherin is one reported mechanism
of down-regulation (26, 27), we examined mRNA levels for E-cadherin and
desmoglein-2 in response to EGF (Figure 3.3.2). In a time course that spanned
2-48 hours, no statistically significant changes in either E-cadherin or
desmoglein-2 transcript levels were evident. We also saw no change in Ecadherin transcript levels using quantitative real time PCR (data not shown).
This result indicates that cadherin expression is being regulated at the protein
level.
In order to elucidate the mechanism for downregulation, we examined
cadherins by immunofluorescence at timepoints that showed statistically
significant decreases in protein levels. In a timecourse that spanned 24 hours,
we saw redistribution of cadherins from the sites of cell-cell contacts. E-cadherin
staining was retained at the cell periphery for up to several hours after EGF
treatment (Figure 3.3.3, upper panel arrow), and evidence of redistribution from
cell borders occurred after 24 hours of exposure. In contrast, internalization of
desmoglein-2 was evident within 6 hours of EGF treatment as determined by
punctate intracellular staining (Figure 3.3.3, lower panel arrow). This supports
the hypothesis that EGF exposure modulates desmosomes earlier than adherens
junctions through distinct mechanisms.
Immunofluorescence staining of the corresponding cytoskeleton partners
showed disruption of the desmosomal-associated cytokeratin network at 6 hours,
the same time frame as that of desmosomal cadherin internalization (Figure
3.3.4). The adherens junction-associated actin cytoskeleton remained intact at

118

this timepoint, consistent with E-cadherin localization remaining at cell-cell
junctions at the plasma membrane, disruption of the actin skeleton was seen at
24 hours post treatment (data not shown). This indicates a functional disruption
of desmosomes that precedes that of adherens junctions.
In order to determine if these observed differences in the kinetics of
junction disruption were due to intrinsic differences in the junctions themselves or
if the differences were stimulus driven, we compared EGF-induced cadherin
internalization against another known disruptor of junctions, low calcium
conditions. In response to low calcium, E-cadherin protein levels were
decreased by 15-30 minutes post removal and undetectable after 24 hours
(Figure 3.3.5). Desmoglein-2 protein was decreased within 2 hours and also was
undetectable after 24 hours of low calcium. This loss of junction due to reduced
extracellular calcium was more rapid compared to the EGF timecourse (Figure
3.3.1 A), where E-cadherin protein levels remained unchanged at 6 hours post
EGF treatment and decreased at 24 hours post treatment. EGF stimulation did
not cause a significant decrease in desmoglein-2 protein levels until 24 hours
post treatment. This suggests not only that the pathways for junctional
modulation differs between EGF stimulation and low calcium removal, but that
the kinetics for junctional disruption differs under both sets of stimuli.
In response to low calcium, both E-cadherin and desmoglein-2 localization
was completely intracellular, and mostly perinuclear at 2 hours post removal
(Figure 3.3.6). When normal calcium levels were restored, however, E-cadherin
was visible at cell borders within 4 hour of restoration (Figure 3.3.6, upper panel
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arrows), while desmoglein-2 was not visible at cell borders until 24 hours post
calcium restoration, indicating that while E-cadherin is rapidly restored to the cell
surface, the kinetics of desmoglein-2 restoration is markedly slower. When
treated with EGF for 24 hours, E-cadherin became very diffuse and almost
undetectable in the cytoplasm (Refer to Figure 3.3.3). Removal of EGF and the
return of cells to basal conditions showed a slower restoration of E-cadherin to
the cell surface than with low calcium (compare to Figure 3.3.6), returning 6
hours after removal of EGF and was still incomplete after 24 hours (Figure 3.3.7,
upper panel, arrows). Restoration of E-cadherin to cell-cell borders was finally
detectable in some cells by 48 hours post EGF reversal (Figure 3.3.8).
Desmoglein-2, however, showed a similar pattern of slow restoration to the cell
surface as in the low calcium reversal (compare to Figure 3.3.6), but only started
to reappear 24 hours after removal of EGF in some cells (Figure 3.3.7, lower
panel, arrowheads). By 48 hours post EGF removal, nearly all cell-cell borders
stained for desmoglein-2. An antibody that recognizes 2 isoforms of the
desmosomal cadherin desmocollin (desmocollin-2, desmocollin-3) revealed
essentially no staining after 48 hours in EGF free conditions. This suggests that
EGF treatment does not have the same effect on the different cadherins.
Collectively, these data support the hypothesis that different mechanisms for
cadherin internalization from the cell surface occur between low calcium and
EGF exposure and that the kinetics between cadherins differ in both disassembly
and reassembly even with two different stimuli.
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These data, taken together, suggest a differential regulation of E-cadherin
and desmoglein-2 by EGF, exemplified by the kinetics in protein downregulation,
corresponding cytoskeletal disruption and decrease in overall cell border
staining. When compared to another stimulus, low calcium, again we saw
differences between cadherins in kinetics of low calcium disruption of junctions
and junctional reassembly once calcium was restored. When compared to
reassembly after EGF removal, we saw not only differences in kinetics between
junctional reassembly, but differences in the kinetics between stimuli. Overall,
these data suggest different itineraries and timelines for cadherins depending on
the individual cadherin in question and the stimuli presented. The variety of
ligands and other stimuli present at the wound margin could be working on
junctional modulation with different results depending on the timing and the
cadherin in question.
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Figure 3.3.1

Cadherin protein levels decrease from membrane pools upon extended
EGF treatment
SCC 12F cells were grown to subconfluence, placed in serum free medium overnight, and then
treated with EGF for various timepoints. A. Whole cell lysates reveal a decrease in both Ecadherin and desmoglein-2 at 24 to 48 hours post EGF treatment. α-catenin, an adherens
junction protein, showed no change. Sequential detergent extraction separates the triton soluble,
or cytoplasmic fraction (B), from the triton insoluble, or membrane associated fraction (C). A
decrease in total desmoglein-2 is evident as early as 6 hours post treatment in the triton soluble,
membrane associated pool, but as early as 2 hours in the triton insoluble, preformed junction
pool. E-cadherin levels decrease by 24 hours in the both fractions. Results are representative of
a minimum of three separate experiments. Bar graphs represent the densitometric quantification
of each lane normalized to no treatment control, with asterisks indicating statistical significance.
(p<0.05)
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Figure 3.3.2

Cadherins are not transcriptionally regulated in response to EGFR
activation.
SCC 12F cells were treated with EGF for various times from 2 hours up to 48 hours. Control cells
had no EGF treatment. Bar graphs represent the densitometric quantification of bands
normalized to no treatment control. No changes in desmoglein-2 or E-cadherin mRNA levels are
seen, suggesting that cadherin protein loss from the junctions is due to a protein downregulation
and not a change in mRNA levels of the genes.
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Figure 3.3.3
EGF dependent relocalization of cadherins timeline differs
SCC 12F cells were treated with EGF for the indicated timepoints. Cells were fixed, and then
probed with E-cadherin or desmoglein-2 antibodies. E-cadherin maintains strong border staining
at 8 hours post EGF treatment (upper panel arrow). Loss of E-cadherin staining from cell borders
is not evident until 24 hours post EGF treatment. In contrast, relocalization of the desmosomal
cadherin desmoglein-2 from cell borders occurs following treatment with EGF for 4-6 hours (lower
panel arrow).
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Figure 3.3.4
Cytoskeletal changes with EGF treatment
The cytoskeletal counterparts cytokeratin and actin also respond differently to EGF treatment.
SCC 12F cells were treated with EGF, fixed, then stained with phalloidin to stain the actin
cytoskeleton, or with the antibody pan-cytokeratin, which labels keratin filaments. Disorganization
of the keratin network is seen at 6 hours (white arrow), while the actin cytoskeleton remains intact
at 8 hours post treatment.
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Figure 3.3.5

Cadherins downregulated after low calcium treatment as soon as 2 hours
post calcium removal.
SCC 12F cells were grown to subconfluence, placed in serum free medium overnight, and placed
in low calcium media for various timepoints. A decrease in E-cadherin protein can be seen as
early as 2 hours in low calcium medium, and is completely undetectable after 6 hours in low
calcium. A decrease in desmoglein-2 is visible as early as 2 hours post treatment, and is
undetectable at 24 hours post low calcium exposure.
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Figure 3.3.6

Short term low calcium reversal presents different kinetics for E-cadherin
and desmoglein-2
SCC 12F cells were serum starved then placed in low calcium media (0.5 mM) for 2 hours. After
2 hours, cells were placed in calcium containing serum free media. E-cadherin is visible at the
cell surface 4 hours after calcium addition, while desmoglein-2 is not visible at the cell surface
until 24 hours after calcium addition, indicating different kinetics responsible for junctional
restoration after disruption by low calcium.
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Figure 3.3.7

Short term reversal from EGF exposure finds different kinetics of
restoration between E-cadherin and desmoglein-2.
SCC 12F cells were serum starved in control lanes, then treated with 20 nM EGF for 24 hours.
After 24 hours, stimulus was removed, by washing away EGF and placing cells in serum free
media for the indicated times. E-cadherin starts to reappear at cell borders by 6 hours of EGF
removal (arrows), while desmoglein-2 starts to reappear at the cell surface at 24 hours after EGF
removal (arrowheads), indicating different kinetics responsible for individual cadherin restoration.
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Figure 3.3.8

Long term reversal of EGF stimulus shows differences in between the
different cadherins
SCC 12F cells were serum starved in control lanes, then treated with 20 nM EGF for 24 hours.
After 24 hours, stimulus was removed, by washing away EGF and placing cells in serum free
media. E-cadherin and desmoglein-2 were restored to the cell surface by 48 hours after EGF
removal, while desmocollins fail to appear at the cell borders, indicating different kinetics
responsible for individual cadherin restoration.
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3.4

EGF Stimulated Cadherin Trafficking Itineraries
Investigation into the possibility of cadherin internalization was based on

the preliminary indication that in response to EGF, desmoglein-2 staining was
punctate and cytoplasmic (Figure 3.3.3). Although there have been several
studies of E-cadherin internalization in response to various growth factors (Kamei
et al., 1999; Palacios et al., 2002; Bryant et al., 2005; Bryant et al., 2007), EGFstimulated trafficking of desmosomal cadherins has not been as well described.
Internalization of desmoglein-3 in response to pemphigus antibody was found to
undergo a clathrin independent internalization and subsequent lysosomal
degradation (Calkins et al., 2006; Delva et al., 2008). EGFR inhibition has been
shown to restore desmosomal cadherins to the cell surface and prevents a
cleavage event seen in the highly motile squamous cell carcinoma line (Klessner
et al., 2008), highlighting the importance of the EGFR regulation for junctional
integrity. EGFR activation stimulates multiple trafficking pathways including
clathrin dependent and independent (Lu et al., 2003; Bryant et al., 2007; Ning et
al., 2007) trafficking itineraries. EGFR itself undergoes a clathrin dependent
route of internalization upon stimulation with EGF(Huang et al., 2004; Sigismund
et al., 2008), although it can undergo clathrin independent internalization under
certain situations such as oxidative stress (Khan et al., 2006).
Although cadherin modulation is an EGFR-stimulated event, we found that
neither E-cadherin nor desmoglein-2 co-localized with the EGFR following EGFR
activation. EGFR internalization preceded that of desmoglein-2 by several hours
(Figure 3.4.1, white arrows). This suggests that while the internalization of
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desmoglein-2 is due to EGFR activation, it does not internalize with the receptor
itself. Dual immunofluorescence staining for both desmoglein-2 and E-cadherin
revealed that desmoglein-2 colocalized with E-cadherin at the cell surface with
no treatment, but did not colocalize with E-cadherin in the cytosol post EGF
treatment (Figure 3.4.2, white arrows), in agreement with our earlier observation
of different staining patterns with single staining over prolonged EGF treatment,
further indicating distinct fates for the two cadherins.
After 6 hours of EGF treatment, desmoglein internalization was evident by
immunofluorescence. To determine whether this internalization occurs through
the classical endosomal pathway or through other internalization pathways, we
used several markers of the classical endosomal pathway (EEA-1, Rabs) as well
as markers for caveolar dependent internalization (caveolin-1). Interestingly,
portions of E-cadherin at the cell membrane colocalized with caveolin-1 at the
cell surface (Figure 3.4.3). However, there was no intracellular co-localization of
either E-cadherin (Figure 3.4.3, arrows) or desmoglein-2 (Figure 3.4.4, arrows)
with caveolin-1, a marker for the caveosomal dependent trafficking. EGF
dependent caveolin-1 endocytosis has been reported previously by our
laboratory, in an ovarian cancer cell line, which mediated integrin α2
internalization (Ning et al., 2007). Desmoglein-2 differs from E-cadherin at the
cell surface as no membrane colocalization was found between desmoglein-2
and caveolin-1. This suggests that while some E-cadherin colocalized in
caveolin-1 rich domains, neither it nor desmoglein-2 internalized with caveolin-1
upon EGF stimulation.
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The next pathway we investigated was the classical endosomal pathway.
EEA-1 is a marker of early endosomes, and while no colocalization of E-cadherin
with EEA-1 was evident at any timepoint, a small portion of desmoglein-2 was
present in EEA-1 positive early endosomes at 6 hours post EGF addition (Figure
3.4.6, white arrows). This indicates that a while a small portion of desmoglein-2
is found in early endosomes, the majority of desmoglein-2 and E-cadherin is not
found in early endosomes after EGF addition.
Although a small amount of desmoglein-2 was detected in early
endosomes, there was no evidence of desmoglein colocalization with rab7
(Figure 3.4.7), a late endocytic vesicle marker, and only a small amount
colocalized with lysotracker, a marker of lysosomes, at 12 hours post EGF
treatment (summarized in Table 3.4.1). The majority of desmoglein-2 colocalized with the recycling marker Rab11 (Figure 3.4.8). In timepoints from 2-6
hours post EGF treatment, desmoglein-2 and rab11 colocalized in small punctate
vesicles both on the plasma membrane and in the cytosol (Figure 3.4.8, white
arrows). This represents a novel internalization pathway for desmoglein-2.
Upon EGF treatment, the desmoglein-2 protein undergoes a predominantly
recycling pathway rather than a lysosomal degradation pathway.
E-cadherin, however, did not colocalize at any timepoint (up to 10 hours
post EGF treatment) with the late endosomal protein Rab-7 (Figure 3.4.9), the
recycling protein Rab-11 (Figure 3.4.10), nor was it found in the lysosome (Table
3.4.1). We can conclude from these findings that another mechanism other than
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internalization and trafficking is responsible for the downregulation of E-cadherin
after EGFR activation.
In contrast to desmoglein-2, EGF treatment revealed a gradual decrease
in the intensity of E-cadherin staining at cell-cell borders without an emergence of
punctate intracellular staining indicative of internalization (see Figures 3.4.2,
3.4.3, 3.4.5, 3.4.9 and 3.4.10). Therefore I tested if E-cadherin could be
undergoing a cleavage event at the plasma membrane. Immunoblotting revealed
a time dependent increase in an 80 kD E-cadherin fragment in the conditioned
medium upon extended EGF treatment that was statistically significant at 18
hours and 24 hours post treatment (Figure 3.4.11). When stripped and probed
for desmoglein-2, we saw no evidence of cleavage products (data not shown).
We then tested if this cleavage event could be prevented by pretreatment with a
broad spectrum MMP inhibitor. I employed an antibody against an intracellular
epitope for immunofluorescent detection of E-cadherin within the cells. I found
loss of E-cadherin staining at the cell borders 19 hours post EGF treatment in
control cells. Cells pretreated with the broad spectrum MMP inhibitor GM6001,
however, retained junctional E-cadherin staining at the plasma membrane
(Figure 3.4.12). The addition of the MMP inhibitor maintained adherens junction
integrity even upon EGF stimulation, indicating an MMP-dependent process for
adherens junction disruption. Conversely, this protection was not extended to
the desmosomal cadherin desmoglein-2, as internalization occurred
independently of the MMP inhibitor (Figure 3.4.13). Thus we can conclude that
the decrease in E-cadherin staining is due at least in part to cleavage events by
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MMPs. This MMP cleavage is not extended to all cadherins, as desmoglein-2 is
not protected from internalization with the addition of inhibitor. This
demonstrates distinct fates for the desmosomal cadherin, desmoglein-2, as
compared to the classical cadherin, E-cadherin, upon EGF stimulation in a
keratinocyte cell line. Protein collected after 24 hours EGF treatment revealed Ecadherin protein levels were decreased as would be expected from Figure 3.3.1,
but when pretreated with the MMP inhibitor GM6001, E-cadherin levels were
restored to control levels (Figure 3.4.1). Desmoglein-2, although partially
protected from downregulation with GM6001, was not restored to control levels.
This suggests that the majority of EGF-dependent E-cadherin downregulation is
due to MMP cleavage. It also indicates that downregulation of desmoglein-2 may
be complex, as a portion of desmoglein-2 protein is protected with the use of the
MMP inhibitor.
Collectively, these data reveal differential fates for E-cadherin and
desmoglein-2 in response to EGF stimulation. While E-cadherin is found in
caveolin rich regions at the cell surface, it does not internalize with caveosomes
or within the classical endosomal pathway. Other investigators have found Ecadherin to undergo micropinocytosis after EGF treatment in a breast cancer cell
line (Bryant et al., 2007) and cleavage after calcium influx (Rios-Doria et al.,
2003) in the same MCF-7 cell line. We find E-cadherin undergoes a cleavage
event at the cell membrane mediated by a member of the MMP family of
proteases. Desmoglein-2, however, takes a different route upon EGF
stimulation, entering the classical endosomal pathway into recycling
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compartments for several hours post EGF treatment. Recognizing the different
fates of cadherins in response to EGF as well as the response of cadherins to
other stiumuli are two parts in understanding the effective mechanisms
necessary for successful reepithelialization.
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Figure 3.4.1

Cadherin internalization does not follow the same timecourse as EGFR
internalization
SCC 12F cells were serum starved, then treated with 20 nM EGF for 30 minutes, fixed, and
probed for the EGFR (green) or junctional cadherin (red). White arrows indicate the internalized
EGF receptor in the cytoplasm. Both junctional cadherins, E-cadherin (left panels) and
desmoglein-2 (right panels) remain intact and at the cell surface for up to 30 minutes post EGF
treatment.
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Figure 3.4.2

Desmoglein-2 does not internalize with E-cadherin. Time dependence for
EGF-stimulated junctional disruption.
SCC 12F cells were treated with 20 nM EGF for the indicated timepoints. Cells were fixed, then
probed with E-cadherin or desmoglein-2 antibodies. The desmosomal cadherin desmoglein-2 is
relocalized from the cell borders following treatment with EGF by 6-8 hours. Note punctate
cytoplasmic staining (white arrows). This pattern differs from that observed for the adherens
junctional cadherin, E-cadherin, where strong border staining is evident at 6 hours post EGF
treatment.
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Figure 3.4.3
E-cadherin does not colocalize intracellularly with caveolin-1
SCC 12F cells were serum starved, then treated with 20 nM EGF for indicated timepoints, fixed,
and probed for the E-cadherin (red) or caveolin-1 (green). E-cadherin colocalizes partially with
caveolin-1 at the cell membrane in control cells, but after EGF stimulation, E-cadherin does not
colocalize with internalized caveolin-1 (white arrows) up to 8 hours post EGF treatment.
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Figure 3.4.4
Desmoglein-2 does not internalize with caveolin-1
SCC 12F cells were serum starved, then treated with 20 nM EGF for indicated times, fixed, and
probed for desmoglein-2 (red) or caveolin-1 (green). Desmoglein-2 does not colocalize with
caveolin-1 in control cells with no treatment nor at 6-8 hours post EGF stimulation, when both
proteins are internalized.
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Figure 3.4.5

E-cadherin does not internalize with the early endosome marker EEA1 after
EGF stimulation
SCC 12F cells were serum starved, then treated with 20 nM EGF for indicated times, fixed, and
probed for EEA-1 (red) or E-cadherin (green). E-cadherin does not colocalize with EEA-1 in
control cells or after EGF stimulation.

140

Figure 3.4.6

Only a small portion of desmoglein-2 colocalizes with the early endosome
marker EEA1
SCC 12F cells were serum starved, then treated with 20 nM EGF for indicated times, fixed, and
probed for desmoglein-2 (green) or EEA-1 (red). A small amount of desmoglein-2 colocalizes with
EEA-1 after 6 hours EGF stimulation (white arrows).
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Figure 3.4.7

Desmoglein-2 does not colocalize with the late endocytic marker Rab7 after
EGF stimulation.
SCC 12F cells were serum starved, then treated with EGF for various times, fixed, and probed for
desmoglein-2 (green) or Rab-7 (red). Although both proteins are cytoplasmic after EGF
activation, no colocalization is seen from 6-10 hours EGF stimulation (white arrows).
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Figure 3.4.8
Desmoglein-2 colocalizes with the recycling marker Rab-11
SCC 12F cells were serum starved, then treated with 20 nM EGF for indicated timepoints, fixed,
and probed for desmoglein-2 (green) or Rab-11 (red). Desmoglein-2 colocalizes with Rab-11 both
at the cell membrane and in the cytoplasm 6 hours post EGF stimulation (white arrows).
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Figure 3.4.9

E-cadherin does not colocalize with the late endosome marker Rab7 after
EGF stimulation.
SCC 12F cells were serum starved, then treated with 20 nM EGF for indicated timepoints, fixed,
and probed for E-cadherin (green) or Rab-7 (red). No colocalization was seen between the two
proteins at any timepoints.
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Figure 3.4.10

E-cadherin does not colocalize with the recycling marker Rab11 upon
EGF stimulation
SCC 12F cells were serum starved, then treated with 20 nM EGF for indicated timepoints, fixed,
and probed for E-cadherin (green) or Rab-11 (red). No colocalization was seen between the two
proteins at any timepoints.
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Table 3.4.1

Summary of colocalization experiments

Desmoglein-2 colocalization
EEA-1 (Early endosome)
(+)
Rab-11 (Recycling endosome)
(+++)
Rab-7 (Late endosome)
(-)
Lysotraker (Lysosome)
(+)
Caveolin-1 (caveosome)
(-)

E-cadherin colocalization
(-)
(-)
(-)
(-)
(+/-)

Key: Colocalization experiments were carried out with immunofluorescence techniques described
above. EGF timecourse ranged from 2-12 hours, and were done a minimum of 3 times. (-)
indicates no colocalization at any timepoint; (+/-) indicates colocalization at the plasma
membrane but not in cytoplasm; (+) indicates colocalization in vesicles at at least one timepoint;
(+++) indicates colocalization in vesicles at several timepoints.
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Figure 3.4.11

Evidence of an 80 kD E-cadherin ectodomain fragment in the conditioned
cell culture medium after EGF treatment.
SCC 12F cells were serum starved overnight in medium without 0.1% BSA, then stimulated with
20 nM EGF for the indicated times. Medium was collected, spun down to remove cellular debris,
then processed as normal on Western blot. Membrane was probed with E-cadherin antibody that
recognized the extracellular portion of the protein. A statistically significant increase in Ecadherin ectodomain was seen at 18 hours post EGF treatment (n=3, p<0.05).
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Figure 3.4.12

Maintenance of cell-cell junctions after EGF treatment with the addition of
broad spectrum MMP inhbitor
SCC 12F cells were serum starved overnight, then treated with 20 nM EGF for indicated
timepoints, either with or without pretreatment with 50 μM GM6001, an MMP inhibitor. Cells were
then fixed, and probed with an antibody that recognizes the intracellular domain of E-cadherin
(green). After 19 hours post EGF treatment, E-cadherin is no longer visible at the cell borders and
the intracellular domain of E-cadherin is detected in the cytoplasm (white arrow, left panel).
However, the presence of GM6001 maintains E-cadherin at the cell borders (white arrow, right
panel).
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Figure 3.4.13

Desmoglein-2 internalization is not prevented with the addition of the broad
spectrum MMP inhibitor GM6001.
SCC 12F cells were serum starved overnight and treated with 20 nM EGF for indicated
timepoints, either with or without pretreatment with 50 μM GM6001, an MMP inhibitor. Cells were
then fixed, and probed with an antibody that recognizes the intracellular domain of E-cadherin
(green). After 6 hours post EGF treatment, desmoglein is no longer visible at the cell borders and
is detected in the cytoplasm (white arrow, left panel). The pretreatment with GM6001 does not
prevent internalization of desmoglein-2 from occuring (white arrow, right panel).
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Figure 3.4.14 E-cadherin, and to a smaller degree, desmoglein-2, are protected from
downregulation by the use of global MMP inhibitor GM6001.
SCC 12F cells were serum starved then treated with 20 nM EGF for indicated timepoints, either
with or without pretreatment with 50 μM GM6001, an MMP inhibitor. Both E-cadherin and
desmoglein-2 decrease after EGF treatment, but only E-cadherin levels are restored to control
levels with pretreatment with the MMP inhibitor. Demsoglein-2 levels are partially restored,
indicating partial protection from cleavage with the MMP inhibitor.
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4 Discussion
This study has investigated consequences of EGFR activation in
keratinocytes to better understand events that occur at the margins of healing
wounds during reepithelialization. I found that elevated EGFR is required for
EGF dependent junctional modulation, including cytoskeletal rearrangement
and translocation of junctional components to initiate changes in gene
transcription. Additionally, I have identified that the mechanisms involved in
EGF-dependent junctional disruption differs for adherens junctions and
desmosomes. While desmoglein-2 enters a recycling pathway after EGF
treatment, E-cadherin undergoes a cleavage event that is MMP dependent. I
have found further differences in the temporal sequence of junctional
modulation between two stimuli, low calcium and EGF. The significance of
these findings is discussed below.

4.1

Elevated EGFR at wound margins and effects
Dynamic regulation of both EGFR and ligand levels occurs at the wound

edge. When EGFR levels are elevated, an autocrine release of EGFR ligand is
produced by keratinocytes that promotes migration. This autocrine regulation of
in vitro repithelializtion cannot be fully compensated by the growth factors and
serum upon EGFR inhibition, indicating that EGFR activation is key in a full
reepithelialization response. In support of this, studies have shown that wound
repair is greatly decreased in mice lacking EGFR (Repertinger et al., 2004).
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Elevated EGFR at wound margins also results in junctional disruption that
releases ß-catenin and a causes a change in the transcription that is consistent
with the needs of reepithelialization. A recent study highlights the importance of
elevated EGFR for successful reepithelialization in humans. Patients with
chronic wounds have a decreased amount of EGFR at the margins as compared
to their own adjacent, healthy skin (Brem et al., 2007). This indicates the
physiological and pathophysiological role for EGFR regulation at wound margins.
Understanding the mechanisms of EGFR dependent reepithelialization could
have clinical benefits for patients with non-healing wounds.
The observation that elevated EGFR leads to junctional disruption and
nuclear localization of ß-catenin has significant implications. ß-catenin can
activate a number of genes necessary for cell survival, proliferation and
migration. Investigators have separated these downstream targets into two
categories, classical and non-classical targets. Classical targets of ß-catenin
include cyclin-D, Myc, and survivin, which are important in cell survival and
proliferation. Non-classical target genes include MMP-14, Slug and tenascin-C,
genes important for migration and an EMT response. Brabletz and coworkers
suggest that in a cancer model, low levels of ß-catenin in the nucleus are
sufficient to stimulate the classical pathway of transcription (Brabletz et al.,
2005). In order to activate the non-classical target genes, however, a second
stimulus, or change in the microenvironment is needed. Examples mentioned
that can induce EMT are HGF, EGF and TGF-ß. This concept originated for
cancer has striking similarities to wound healing. In both tumor metastasis and
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wound healing, there is a need for cell migration and an overall EMT event. We
find that a change in the microenvironment, wounding, elevates EGFR and ligand
levels which result in translocation of ß-catenin and activation of non-classical
target genes Slug and tenascin-C, both of which are required for effective wound
repair. Differences in tumor metastasis and wound healing involve the fact that
wound healing represents a partial EMT (Arnoux, 2005), and reversion is needed
back to an epithelial state, although some tumors do dedifferentiate to epithelial
status after invasion (Jeanes et al., 2008). Further studies are needed to fully
understand the range of genes affected by EGFR activated ß-catenin
transcriptional regulation.
Questions that remain unanswered are: 1.) why is EGFR upregulated at
wound margins and 2.) what are the signals that initiate this upregulation. The
answers to these questions are currently unknown, but one possibility is that
adhesion serves as a cue and disruption of adhesion starts signaling cascades
that leads to EGFR upregulation. One example in the literature that supports this
hypothesis is the fact that soluble E-cadherin fragments were able to bind ErbB2
and stabilize its association with ErbB3 and increase downstream Erk signaling
(Najy et al., 2008). Other possibilites are the myriad of other factors that are
present in the wound microenvironment released by inflammatory cells. Future
experiments to investigate the roles of these other factors available during wound
healing could give insight into regulation of modulation of cell-cell junctions
during reepithelialization
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4.2 Mechanisms of EGF dependent modulation differ between
E-cadherin and desmoglein-2
Another significant finding is that different mechanisms are responsible for
EGF dependent modulation of E-cadherin and desmoglein-2. I investigated the
effects of EGFR activation on the fate of the adherens junction protein Ecadherin and the desmosomal cadherin desmoglein-2 in vitro. Upon extended
EGF treatment, desmoglein-2 is internalized and enters a recycling pathway that
lasts up to 8 hours post stimulus. Other studies have shown internalization of Ecadherin in response to EGF treatment (Bryant et al., 2007), as well as a variety
of other stimuli in different cell types (Table 4.2.1). However, we find that in SCC
12F cells, E-cadherin remains at cell-cell borders until 18-19 hours post EGF
treatment. After 18-19 hours post EGF treatment, E-cadherin ectodomain can be
found in the medium and cell border staining is decreased, in a process that can
be prevented with a MMP inhibitor. This suggests a direct link between MMPs
and E-cadherin cleavage after EGFR stimulation. While there are several
examples of MMP dependent E-cadherin cleavage (Davies et al., 2001; Noe et
al., 2001; Symowicz et al., 2007; Cowden Dahl et al., 2008), this is the first
example of a desmosomal cadherin entering a recycling pathway in response to
growth factor activation. Wound repair is a dynamic process and rapid
reassembly after reepithelialization is complete is crucial to the restoration of a
functional barrier, so it stands to reason that desmosomal cadherins entering a
recycling pathway would be beneficial to cells undergoing reepithelialization.
There are many different mechanisms reported for junctional disruption,
including low calcium (discussed in the previous section give section number)
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(1), transcriptional repression (2), phosphorylation events (3), internalization and
trafficking (4) and proteolytic cleavage (5) (See Figure 4.2.1).
Transcriptional repression (Figure 4.2.1, part 2) of E-cadherin, ß-catenin,
desmoglein-2 or plakoglobin was not observed under our conditions, however,
transcriptional repression of cadherins represents an important mechanism in
invasive cancers. Transcriptional repression is a mechanism employed in human
breast cancer samples for desmosomal downregulation. In 32 tumor samples,
72% had decreased mRNA expression of desmocollin-3 and of these, 56% had
hypermethylated promoter regions, a known epigenetic mechanism of gene
silencing (Oshiro et al., 2005). A recent study revealed that the repression of
desmocollin-2 gene was due to transcription factors CDX1 and CDX2, repression
of these transcription factors restored a normal epithelial morphology (Funakoshi
et al., 2008).
Several mediators can activate a Slug induced repression of E-cadherin,
including activation of the Notch pathway (Leong et al., 2007), calreticulin
(Hayashida et al., 2006), estrogen (Park et al., 2008), TGF-ß (Choi et al., 2007),
and FGF-1 (Savagner et al., 1997). Slug/Snai2 represses E-cadherin in tumors
(Uchikado et al., 2005; Come et al., 2006) and overexpression of Slug in a rat
bladder carcinoma cell line led to an EMT like response (Savagner et al., 1997).
The absence of Slug is associated with a retention of adherens junction protein
at the wound margin (Chandler et al., 2007).
We did not investigate if phosphorylation events (Figure 4.1 part 3) occur
in our system due to the fact that phosphorylation typically induces a rapid (within
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minutes) downregulation of proteins, and we do not see changes in cadherins for
several hours. Many others have reported growth factor addition to cause
phosphorylation of cadherins. In MDCK cells, HGF treatment caused Src
activation, which led to tyrosine phosphorylation of E-cadherin, ubiquitination by
the E3 ubiquitin ligase Hakai and internalization by 4 hours post treatment (Fujita
et al., 2002). PKC-α can modulate desmosomal components directly, via serine
phosphorylation of desmoplakin (Amar et al., 1999), which serves to stabilize the
junction. Tyrosine phosphorylation of desmoglein-2 is prevented by inhibition of
the EGFR in a invasive SCC cell line, which results in reassembly of
desmosomal junctions and overall increased intracellular adhesion (Lorch et al.,
2004). Phosphorylation events, therefore, may be more important for initial
assembly and reassembly than for junctional disruption.
The internalization of cadherins and cadherin trafficking has been studied
in several models (Figure 4.2.1, part 4). We find the desmosomal cadherin
desmoglein-2 to enter a recycling pathway after EGF stimulation. Although this
is the first desmosomal cadherin shown to enter this pathway after growth factor
treatment, E-cadherin has been shown in to enter a recycling pathway at basal
conditions. Overexpression of a GFP tagged E-cadherin showed colocalization
of the cadherin with Rab11, the endocytic recycling marker (Lock and Stow,
2005), and nascent, post-Golgi E-cadherin uses the recycling pathway to sort to
the plasma membrane in MDCK cells (Lock and Stow, 2005). The use of Ecadherin mutants revealed that E-cadherin that cannot bind p120 colocalizes with
both early and recycling endosomes (Miyashita and Ozawa, 2007b).
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We found no evidence of E-cadherin entering the lysosome for
degradation, but a small portion of desmoglein-2 was found in lysosomes after
extended timepoints of EGF treatment. This could indicate a similar process in
which after being in the recycling pathway for an extended period of time,
desmoglein-2 is shuttled to the lysosome for degradation. However, since only a
small amount of desmoglein-2 was found in the lysosome, we can assume that
either only a portion of desmoglein undergoes recycling and degradation or that
the recycling and degradation of total desmoglein occurs asynchronously.
Another mechanism of cell-cell junction disruption is proteolytic cleavage
(Figure 4.2.1, part 5). We found evidence of MMP dependent cleavage of Ecadherin that was not extended to the desmosomal cadherin desmoglein-2,
although it is possible that cleavage of desmoglein-2 occurred that was below our
detection limits. Desmosomal components have been reported to undergo
cleavage in response to different stimuli. Desmoglein-3, in response to
autoimmune antibodies produced in patients with pemphigus vulgaris caused
internalization and lysosomal degradation by 3 hours post treatment (Calkins et
al., 2006). Desmoglein-3 fragmentation in response to apoptosis occurs by
MMP-9 (Cirillo et al., 2007). The same laboratory found cleavage products of
desmoglein-3 in response to pemphigus vulgaris autoantibodies (Cirillo et al.,
2008a). In a highly invasive squamous cell line that forms sparse cell cell
junctions, an 100 kD desmoglein-2 fragment was detected in low calcium
(.09mM) conditions that was decreased upon both EGFR and MMP inhibition
(Lorch et al., 2004). Using the same system, the Green laboratory showed
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production of the 100 kD fragment of desmoglein-2 was blocked upon inhibition
of the protease ADAM17 (Klessner et al., 2008). ADAM17 was predicted to
cleave several substrates, including desmoglein-2, in proteomic analysis (BechSerra et al., 2006). Collectively, these studies suggest that some desmosomal
constituents may be sensitive to cleavage as a mechanism of junctional
disruption. This is consistent with our findings that a small but detectable amount
of desmoglein-2 was protected with the use of an MMP inhibitor (Figure 3.4.14).
During wound healing, several MMPs are expressed by keratinocytes at
the migrating wound edge, including, collagenase MMP-1, gelatinase MMP-9,
and stromelysins MMP-3 and MMP-10 (Madlener et al., 1998). Of these MMPs,
two are reported to cleave E-cadherin in response to TPA treatment (Noe et al.,
2001) and EGF (Cowden Dahl et al., 2008). In SCC 12F cells, we found MMP
production and cell motility to be stimulus dependent, as EGF, TGF-α, and
HGF/SF can cause colony dispersion and increased MMP production while other
growth factors such as KGF and IGF-1 had no effect (McCawley et al., 1998).
Although there is evidence for transcriptional regulation, phosphorylation,
internalization and proteolytic cleavage of cadherins in various different cells, we
find that upon EGF stimulation, E-cadherin undergoes a MMP dependent
cleavage event and desmoglein-2 enters a recycling pathway in human
keratinocytes. Multiple mechanisms can occur with a given cell type for the same
cadherin. A good example is the in the well studied Madin-Darby canine kidney
(MDCK) epithelial cell line, in which various fates of E-cadherin (Figure 4.2.2)
have been reported. As mentioned earlier, E-cadherin in MDCK cells undergo
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recycling under basal conditions (Lock and Stow, 2005). However, two
independent investigators have found E-cadherin to colocalize with caveolin-1 at
the cell membrane in MDCK cells (Galbiati et al., 2000; Palacios et al., 2002),
and both E-cadherin and ß-catenin have also been found to colocalize and
coimmunoprecipitate with caveolin-1 under basal conditions. In low calcium,
MDCK cells internalize E-cadherin into a recycling endosome and addition of
calcium back to the media restores E-cadherin to the cell surface unless a
recycling inhibitor is present (Le et al., 1999). Others have reported addition of
low calcium shuts E-cadherin from a recycling pathway to degradation in the
lysosome (Shen et al., 2008). Clathrin dependent endocytosis (Palacios et al.,
2002), lysosomal degradation (Palacios et al., 2005), cleavage by plasmin
(Ryniers et al., 2002), and tyrosine phosphorylation (Fujita et al., 2002) has also
been reported to occur to E-cadherin in MDCK cells (Figure 4.2.2).
Transcriptional repression by Slug and SIP-1 are 2 other mechanisms for Ecadherin downregulation in MDCK cells (Comijn et al., 2001; Bolos et al., 2003).
Multiple mechanisms can occur within a given cell type for the same protein. Ecadherin was reported to undergo internalization, phosphorylation and
transcriptional regulation in MDCK cells. One explanation for the differences is
the initial stimulus presented to the cells. Wound reepithelialization is a dynamic,
multifaceted process in which signals in the microenvironment change in a
temporal sequence. Although certain responses were not detected in this study,
it does not preclude them from being possible contributors in the overall process
of reepithelialization.
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Figure 4.2.1
Mechanisms of junctional disruption
Several reported mechanisms of junctional disruption. All events listed have been reported to
occur to cadherins as a mechanism for downregulation.
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Figure 4.2.2
E-cadherin trafficking in response to stimuli in MDCK cells
Examples of differential regulation of E-cadherin after various stimuli in the MDCK cell line. Note
that some stimuli, such as Src activation has been reported to have several different effects on Ecadherin in the same cell line.
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4.3 Stimulus dependent regulation of cadherins assembly and
disassembly
A related finding to the differential regulation of E-cadherin and
desmoglein-2 is the differences in kinetics for each junctional cadherin with both
EGF stimulation and low calcium, and the differences that occur after reversal of
each stimulus. Not much is known about junctional modulation at wound
margins, however, there are some early studies conducted on assembly of
desmosomes and there is evidence of modulation in invasive cancers.
Early studies on desmosomal disassembly/reassembly focused on
disruption of junctions by low calcium conditions, then reassembly after
restoration of calcium levels. The half life of desmogleins 1-3 and desmoplakins
1-2 are decreased rapidly after placement in low calcium (Penn et al., 1987) but
continue to assemble what was described as “half desmosomes” (Duden and
Franke, 1988) that were constitutively endocytosed in a clathrin independent
manner in cytoplasmic vesicles that do not colocalize with early endosomes or
lysosomal markers, but do colocalize with late endosomes (Holm et al., 1993;
Burdett and Sullivan, 2002). The desmosomal cadherins desmoglein-1 and
desmocollin-2 were found to be transported from the Golgi to the plasma
membrane in two stages, first in 60 nM vesicles, then in 200 nM vesicles (Burdett
and Sullivan, 2002). When MDCK cells were returned from low calcium levels to
high calcium levels, desmoplakin associated with intermediate filaments, which
were aligned with the actin cytoskeleton in mouse primary keratinocytes (Green
et al., 1987). The Holm group found that actin depolymerization, but not
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microtubule disruption, inhibited low calcium desmosomal disassembly. Actin
disruption, the cytoskeletal component linked to adherens junctions inhibiting
desmosomal disassembly is an interesting finding when we compare
disassembly to assembly. E-cadherin and preformation of adherens junctions
are required for desmosome assembly (Lewis et al., 1997), so it appears that the
two junctions are intertwined at both assembly and disassembly. Desmosomes
cannot internalize if the adherens junctions and cytoskeletal network are
disturbed, and desmosomes cannot reform once broken until adherens junctions
are in place. Our studies are in agreement with these findings, as we find
desmosomal disruption to occur before that of adherens junctions, as well as
reassembly of desmosomal junctions after both low calcium and EGF reversal to
occur after that of adherens junctions.
Another way to look at reassembly is to take invasive cancer cells with few
cell-cell junctions and modulate their signaling to increase adhesion, such as
inhibition of EGFR. Inhibition of the EGF receptor allows accumulation of
desmoglein-2 and desmoplakin at cell-cell borders in an oral SCC line that
overexpresses EGFR (Lorch et al., 2004). These cells also express a 100kD
cleavage product of desmoglein-2, which could be reversed by inhibition of the
EGFR and several members of the sheddase family of ADAMs, including
ADAM17 (Klessner et al., 2008). Our disassembly studies do not suggest
desmoglein-2 cleavage event, cleavage products of desmoglein-2 were
undetected in the conditioned medium. It is possible amounts could be present
that are below our detection limit. Using the MMP inhibitor GM6001 did not
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inhibit the internalization of desmoglein-2, yet it is possible that other proteases
could be mediating cleavage. It appears that adherens junctions and
desmosomes are linked in reassembly and disassembly, but mechanistic
differences are responsible depending on the method of stimulus, be it a calcium
switch method or EGFR inhibition in cells with few junctions. In agreement with
this hypothesis, we find temporal differences in both internalization and
downregulation of junctions in response to low calcium versus EGF treatment.
Stimulus then, seems to dictate the type of junctional modulation in both
reassembly and disassembly. When we look at the various types of stimuli in
and the resulting effects on E-cadherin, we see a variety of effects (See Table
4.3.1). Basal E-cadherin associates with caveolin at the plasma membrane
(Galbiati et al., 2000; Palacios et al., 2002), but is also seen to enter clathrin
dependent recycling pathway in MDCK cells (Le et al., 1999). Low calcium
conditions cause clathrin dependent endocytosis (Ivanov et al., 2004), recycling
(Ling et al., 2007), caveolar dependent endocytosis (Akhtar and Hotchin, 2001)
and lysosomal degradation (Shen et al., 2008) depending on the cell type. In
response to overexpression of the tyrosine kinase Src, clathrin dependent
endocytosis and lysosomal degradation was observed in MDCK cells (Palacios
et al., 2005). EGF treatment is reported to cause micropinocytosis of E-cadherin
(Bryant et al., 2007) in MCF-7 cells and caveolar dependent internalization (Lu et
al., 2003) in A431. HGF treatment in these cells resulted in both dynamin
dependent endocytosis (Palacios et al., 2002) and co-internalization into early
endosomes with the tyrosine kinase receptors c-Met in response to HGF
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treatment (Kamei et al., 1999). TPA induced activation of protein kinase C (PKC)
induced endocytosis and recycling of E-cadherin (Le et al., 2002). Clearly, there
are several different internalization mechanisms available to E-cadherin
depending on the cell type and stimulus.
In my studies with the SCC 12F cell line with the Src inhibitor SU6656, I
find that desmoglein-2 internalization occurs independent of Src (data not
shown). Although many groups have reported E-cadherin internalization
dependent on Src (Palovuori et al., 2003; Palacios et al., 2005; Shen et al.,
2008), in support of my findings, another group found that Src activation was not
necessary for the overall breakdown of tight junctions and transformation to a
mesenchymal phenotype (Maeda et al., 2006). This strengthens our hypothesis
of differential fates of junctional cadherins dependent on both the stimulus and
the junction in question. One unanswered question is the reason for time delay
in between the initial EGF stimulation and cadherin response. One possibility is
the necessity for new protein synthesis or RNA synthesis to occur. One glimpse
that this might be possible came by work in our lab by Jennifer Halblieb, who
used cycloheximide, a protein synthesis inhibitor before EGF treatment, and
found E-cadherin remained at the cell surface after 24 hours. New protein
synthesis of MMPs could be required for E-cadherin cleavage to occur. I used
cycloheximide and treated cells for 6 hours with EGF, and internalization of
desmoglein-2 still occurred (data not shown), indicating that no new protein
synthesis is necessary for the internalization of desmoglein-2. It would have been
interesting to see what the results of EGF reversal and junctional reassembly
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would be, since E-cadherin and adherens junction assembly is required for
desmosomal assembly. I would predict that without new protein synthesis of
MMPs, E-cadherin would already be assembled at adherens junctions and the
restoration of desmosomes would occur much more quickly.
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Table 4.2.1

Stimulus
None

Stimulus dependent internalization of E-cadherin

MDCK cells
Reference

Other cells

Caveolar association at PM;
clathrin dependent recycling

Reference

Clathrin independent
dynamin dep (MCF-7, CHO)

(Galbiati et al., 2000; Palacios et al., 2002); (Paterson et al., 2003))
(Le et al., 1999)

Low calcium clathrin dependent endocytosis,
recycling
(Ivanov et al., 2004; Ling et al., 2007)

Src

clathrin dependent endocytosis;
lysosomal degradation

HGF

dynamin dependent endocytosis;
Early endosomes with receptor

TGF-ß

Recycling

caveolar dep (SCC12F);
lysosomal degradation (MCF-7)
(Akhtar and Hotchin, 2001);
(Shen et al., 2008)

(Palacios et al., 2005)

(Palacios et al., 2002); (Kamei et al., 1999)
(Le et al., 2002)

EGF

micropinocytosis (MCF-7);
caveolar endocytosis (A431)
(Bryant et al., 2007); (Lu et al., 2003)

FGF

Early endosomes with receptor
(MCF-7)
(Bryant et al., 2005)

TPA

lysosomal degrdation
(Shen et al., 2008)

Key: PM = plasma membrane, CHO= chinese hamster ovary cells, HGF = hepatocyte growth
factor, TGF-ß = transforming growth factor beta, EGF = epidermal growth factor, FGF =
fibroblast growth factor, TPA = 12-O-tetradecanoylphorbol-13-acetate
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4.4

Conclusions
Overall, junctional modulation is a dynamic process. Several variables,

such as cell type, stimulus presented as well as the junction in question affect the
route or eventual fate of the junctional component. Regulation of junctional
modulation during wound healing is likely due to specific extracellular signals
and these extracellular signals are dynamic, and change within the time
sequence of wound healing. We find distinct pathways of junctional modulation
that occurs with elevated EGFR levels and activation with EGF. Although in this
cell line, with this stimulus, we see E-cadherin cleavage and desmoglein-2
recycling, other signals at different timepoints could lead to very different results.
Future studies should involve 1) mechanisms that cause elevation of EGFR at
the wound margin, 2) dissection of the temporal sequence of signals other than
EGF that are also present in the wound microenviroment and their effects on
junctional modulation, and 3) how different signals change the fate and itinerary
of junctional cadherins. These questions will need to be addressed before we
have a full picture of junctional dynamics during reepithelialization.
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